



INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED GUIDELINE
GOOD CLINICAL PRACTICE (GCP)
E6(R3)

Draft version

Endorsed on 19 May 2023

Currently under public consultation

At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

E6(R3)

Document History

Code	History	Date
E6	Approval by the Steering Committee under <i>Step 2</i> and release for public consultation.	27 April 1995
E6	Approval by the Steering Committee under <i>Step 4</i> and recommended for adoption to the three ICH regulatory bodies.	1 May 1996
E6(R1)	Approval by the Steering Committee of Post- <i>Step 4</i> editorial corrections.	10 June 1996
E6(R2)	Adoption by the Regulatory Members of the ICH Assembly under <i>Step 4</i> . Integrated Addendum to ICH E6(R1) document. Changes are integrated directly into the following sections of the parental Guideline: Introduction, 1.63, 1.64, 1.65, 2.10, 2.13, 4.2.5, 4.2.6, 4.9.0, 5.0, 5.0.1, 5.0.2, 5.0.3, 5.0.4, 5.0.5, 5.0.6, 5.0.7, 5.2.2, 5.5.3 (a), 5.5.3 (b), 5.5.3 (h), 5.18.3, 5.18.6 (e), 5.18.7, 5.20.1, 8.1	9 November 2016
E6(R3)	Endorsement by the Members of the ICH Assembly under <i>Step 2</i> and release for public consultation.	19 May 2023

Legal notice: This document is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.

The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.

The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

ICH HARMONISED GUIDELINE
GOOD CLINICAL PRACTICE (GCP)
E6(R3)

ICH Consensus Guideline

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
	Guideline Scope.....	1
	Guideline Structure	1
II.	PRINCIPLES OF ICH GCP.....	2
III.	ANNEX 1	7
1.	INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC).....	7
1.1	Responsibilities.....	7
1.2	Composition, Functions and Operations	9
1.3	Procedures	9
1.4	Records.....	10
1.5	Submission and Communication	11
2.	INVESTIGATOR	11
2.1	Qualifications and Training.....	11
2.2	Resources	11
2.3	Responsibilities.....	11
2.4	Communication with IRB/IEC	12
2.5	Compliance with Protocol	12
2.6	Premature Termination or Suspension of a Trial.....	13
2.7	Participant Medical Care and Safety Reporting.....	13
	<i>2.7.1 Medical Care of Trial Participants</i>	<i>13</i>
	<i>2.7.2 Safety Reporting</i>	<i>14</i>
2.8	Informed Consent of Trial Participants	14
2.9	End of Participation in a Clinical Trial	18
2.10	Investigational Product Management.....	19
2.11	Randomisation Procedures and Unblinding	19

2.12	Records.....	20
2.13	Clinical Trial/Study Reports	21
3.	SPONSOR.....	22
3.1	Trial Design	22
3.2	Resources	22
3.3	Allocation of Activities.....	22
3.4	Qualification and Training.....	22
3.4.1	<i>Medical Expertise.....</i>	<i>22</i>
3.5	Financing	23
3.6	Agreements	23
3.7	Investigator Selection.....	24
3.8	Communication with IRB/IEC and Regulatory Authority(ies)	24
3.8.1	<i>Notification/Submission to Regulatory Authority(ies)</i>	<i>24</i>
3.8.2	<i>Confirmation of Review by IRB/IEC</i>	<i>25</i>
3.9	Sponsor Oversight.....	25
3.10	Quality Management	26
3.10.1	<i>Risk Management</i>	<i>26</i>
3.11	Quality Assurance and Quality Control	27
3.11.1	<i>Quality Assurance</i>	<i>27</i>
3.11.2	<i>Audit</i>	<i>27</i>
3.11.3	<i>Quality Control.....</i>	<i>28</i>
3.11.4	<i>Monitoring.....</i>	<i>28</i>
3.12	Noncompliance	33
3.13	Safety Assessment and Reporting.....	33
3.13.1	<i>Sponsor Review of Safety Information</i>	<i>34</i>
3.13.2	<i>Safety Reporting</i>	<i>34</i>
3.13.3	<i>Managing an Immediate Hazard.....</i>	<i>35</i>
3.14	Insurance/Indemnification/Compensation to Participants and Investigators	35
3.15	Investigational Product(s)	35
3.15.1	<i>Information on Investigational Product(s).....</i>	<i>35</i>
3.15.2	<i>Manufacturing, Packaging, Labelling and Coding Investigational Product(s)</i>	<i>35</i>

3.15.3	<i>Supplying and Handling Investigational Product(s)</i>	36
3.16	Data and Records	37
3.16.1	<i>Data Handling</i>	37
3.16.2	<i>Statistical Programming and Data Analysis</i>	41
3.16.3	<i>Record Keeping and Retention</i>	41
3.16.4	<i>Record Access</i>	42
3.17	Reports	42
3.17.1	<i>Premature Termination or Suspension of a Trial</i>	42
3.17.2	<i>Clinical Trial/Study Reports</i>	42
4.	DATA GOVERNANCE – INVESTIGATOR AND SPONSOR	43
4.1	Safeguard Blinding in Data Governance	43
4.2	Data Life Cycle Elements	44
4.2.1	<i>Data Capture</i>	44
4.2.2	<i>Relevant Metadata, Including Audit Trails</i>	44
4.2.3	<i>Review of Data and Metadata</i>	45
4.2.4	<i>Data Corrections</i>	45
4.2.5	<i>Data Transfer, Exchange and Migration</i>	45
4.2.6	<i>Finalisation of Data Sets Prior to Analysis</i>	45
4.3	Computerised Systems	45
4.3.1	<i>Procedures for the Use of Computerised Systems</i>	46
4.3.2	<i>Training</i>	46
4.4	Security of Computerised Systems	46
4.5	Validation of Computerised Systems	46
4.6	System Failure	47
4.7	Technical Support	47
4.8	User Management	48
	GLOSSARY	49
	APPENDICES	58
	Appendix A. INVESTIGATOR’S BROCHURE	58
A.1	Introduction	58
A.2	General Considerations	59
A.2.1	<i>Title Page</i>	59

A.2.2	<i>Confidentiality Statement</i>	59
A.3	Contents of the Investigator's Brochure.....	59
A.3.1	<i>Table of Contents.....</i>	59
A.3.2	<i>Summary.....</i>	59
A.3.3	<i>Introduction</i>	59
A.3.4	<i>Physical, Chemical and Pharmaceutical Properties and Formulation</i>	59
A.3.5	<i>Nonclinical Studies.....</i>	60
A.3.6	<i>Effects in Humans.....</i>	61
A.3.7	<i>Summary of Data and Guidance for the Investigator</i>	62
Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)		
	<i>.....</i>	64
B.1	General Information.....	64
B.2	Background Information	64
B.3	Trial Objectives and Purpose	64
B.4	Trial Design	65
B.5	Selection of Participants	65
B.6	Withdrawal of Consent or Discontinuation of Participation.....	65
B.7	Treatment and Interventions for Participants	66
B.8	Assessment of Efficacy.....	66
B.9	Assessment of Safety	66
B.10	Statistical Considerations.....	66
B.11	Direct Access to Source Records	67
B.12	Quality Control and Quality Assurance	67
B.13	Ethics.....	67
B.14	Data Handling and Record Keeping	67
B.15	Financing and Insurance.....	67
B.16	Publication Policy.....	67
Appendix C. ESSENTIAL RECORDS FOR THE CONDUCT OF A CLINICAL TRIAL		
	<i>.....</i>	68
C.1	Introduction.....	68
C.2	Management of Essential Records	68
C.3	Essentiality of Trial Records.....	69

I. INTRODUCTION

Good Clinical Practice (GCP) is an international, ethical, scientific and quality standard for the conduct of trials that involve human participants. Clinical trials conducted in accordance with this standard will help to assure that the rights, safety and well-being of trial participants are protected; that the conduct is consistent with the principles that have their origin in the Declaration of Helsinki; and that the clinical trial results are reliable. The term “trial conduct” in this document includes processes from planning to reporting, including planning, initiating, performing, recording, oversight, evaluation, analysis and reporting activities as appropriate.

The objective of this ICH GCP Guideline is to provide a unified standard to facilitate the mutual acceptance of clinical trial data for ICH member countries and regions by applicable regulatory authorities.

This guideline builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies. This includes fostering a quality culture and proactively designing quality into clinical trials and drug development planning, identifying factors critical to trial quality, and engaging stakeholders, as appropriate, using a proportionate risk-based approach.

Clinical trials vary widely in scale, complexity and cost. Careful evaluation of the priorities involved in each trial and the risks associated with the priorities will help ensure efficiency by focusing on activities critical to achieving the trial objectives.

Guideline Scope

This guideline applies to interventional clinical trials of investigational products¹ that are intended to be submitted to regulatory authorities. This guideline may also be applicable to other interventional clinical trials of investigational products that are not intended to support marketing authorisation applications in accordance with local requirements.

Guideline Structure

This ICH GCP Guideline is composed of principles and annexes that expand on the principles, with specific details for different types of clinical trials. The principles are intended to apply across clinical trial types and settings and to remain relevant as technological and methodological advances occur. The principles outlined in this guideline may be satisfied using differing approaches and should be applied to fit the intended purpose of the clinical trial.

Annex-1 is intended to provide information on how the principles can be appropriately applied to clinical trials. Additional annexes may be developed to respond to stakeholder needs and to address emerging innovations in trial design and conduct. This guideline should be read in conjunction with other ICH guidelines relevant to the design and conduct of clinical trials, including multiregional trials.

¹ For the purpose of this guideline, the term “investigational products” should be considered synonymous with drugs, medicines, medicinal products, vaccines and biological products.

II. PRINCIPLES OF ICH GCP

Clinical trials are a fundamental part of clinical research that support the development of new medicines or uses of existing medicines. Well-designed and conducted clinical trials help answer key questions in healthcare and drug development. Their results are essential for evidence-based healthcare decisions. Trials with inadequate design and/or poorly conducted trials may place participant safety at risk and yield inadequate or unreliable evidence and are unethical. They waste resources and the efforts and time of investigators and participants.

The principles of GCP are designed to be flexible and applicable to a broad range of clinical trials. This guideline, along with ICH E8(R1), encourages thoughtful consideration and planning to address specific and potentially unique aspects of an individual clinical trial. This includes evaluation of trial characteristics, such as the design elements, the investigational product being evaluated, the medical condition being addressed, the characteristics of the participants, the setting in which the clinical trial is being conducted, and the type of data being collected. Careful consideration of factors relevant to ensuring trial quality is needed for each clinical trial.

The principles are intended to support efficient approaches to trial design and conduct. For example, innovative digital health technologies, such as wearables and sensors, may expand the possible approaches to trial conduct. Such technologies can be incorporated into existing healthcare infrastructures and enable the use of a variety of relevant data sources in clinical trials. This will aid in keeping clinical trial conduct in line with advancing science and technological developments. The use of technology in the conduct of clinical trials should be adapted to fit the participant characteristics and the particular trial design. This guideline is intended to be media neutral to enable the use of different technologies for the purposes of documentation.

The use of innovative clinical trial designs and technologies may help include diverse patient populations, as appropriate, and enable wider participation. The design of the trial, to ensure appropriate quality and meaningful trial outcomes, may be supported by the perspectives of stakeholders; for example, patients and/or healthcare providers. Their input can increase the likelihood of meaningful trial outcomes, which are relevant to both trial participants and future patients. This input will also guide decisions on the feasibility of data collection and assure that participation in the trial does not become unduly burdensome for those involved.

Clinical trials should be designed to protect the rights, safety and well-being of participants and assure the reliability of results. Quality by design should be implemented to identify the factors (i.e., data and processes) that are critical to ensuring trial quality and the risks that threaten the integrity of those factors and ultimately the reliability of the trial results. Clinical trial processes and risk mitigation strategies implemented to support the conduct of the trial should be proportionate to the importance of the data being collected and the risks to trial participant safety and data reliability. Trial designs should be operationally feasible and avoid unnecessary complexities.

The overarching principles provide a flexible framework for clinical trial conduct. They are structured to provide guidance throughout the life cycle of the clinical trial. These principles are applicable to trials involving human participants. The principles are interdependent and should be considered in their totality to assure ethical trial conduct and reliable results.

1. Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with GCP and applicable regulatory requirement(s). Clinical trials should be designed and conducted in ways that ensure the rights, safety and well-being of participants.

- 1.1 The rights, safety and well-being of the participants are the most important considerations and should prevail over interests of science and society.
- 1.2 The safety of the participants should be reviewed periodically as new safety information becomes available, which could have an impact on the participant or the conduct of the trial.
- 1.3 Foreseeable risks and inconveniences should be weighed against the anticipated benefits for the individual participants and society. A trial should be initiated and continued only if the anticipated benefits justify the known and anticipated risks.
- 1.4 When designing a clinical trial, the scientific goal and purpose should be carefully considered so as not to unnecessarily exclude particular participant populations. The participant selection process should be representative of the anticipated population who is likely to use the medicinal product in future clinical practice to allow for generalising the results across the broader population. Certain trials (e.g., early phase, proof of concept trials, bioequivalence studies) may not require a heterogeneous population.
- 1.5 A qualified physician or, when appropriate, a qualified dentist (or other qualified healthcare professionals in accordance with local regulatory requirements) should have the overall responsibility for the trial-related medical care given to, and medical decisions made on behalf of, participants; however, the practical interactions and the delivery of medical care and decisions can be carried out by appropriately qualified healthcare professionals in accordance with applicable regulatory requirements.
- 1.6 The confidentiality of information that could identify participants should be protected in accordance with applicable privacy and data protection requirements.

2. Informed consent is an integral feature of the ethical conduct of a trial. Clinical trial participation should be voluntary and based on a consent process that ensures participants (or their legally acceptable representatives, where applicable) are well-informed.

- 2.1 Freely given informed consent should be obtained and documented from every participant prior to clinical trial participation. For potential participants unable to provide informed consent, their legally acceptable representative should provide consent prior to clinical trial participation.
- 2.2 The process and information provided should be designed to achieve the primary objective of enabling potential trial participants to evaluate the benefits and risks of participating in the trial and to make an informed decision on whether or not to participate in the trial. The information provided during the

- informed consent process should be clear and concise so as to be understandable by potential participants or legally acceptable representatives.
- 2.3 The informed consent process should take into consideration relevant aspects of the trial, such as the characteristics of the participants, the trial design, the anticipated benefit and risk of medical intervention(s), the setting and context in which the trial will be conducted (e.g., trials in emergency situations), and the potential use of technology to inform participants (or their legally acceptable representatives) and obtain informed consent.
- 3. Clinical trials should be subject to an independent review by an institutional review board/independent ethics committee (IRB/IEC).**
- 3.1 A trial should always be conducted in compliance with the protocol that receives prior IRB/IEC approval/favourable opinion.
- 3.2 Periodic review of the trial by the IRB/IEC should also be conducted in accordance with applicable regulatory requirements.
- 4. Clinical trials should be scientifically sound for their intended purpose and based on robust and current scientific knowledge and approaches.**
- 4.1 The available nonclinical and clinical information on an investigational product(s) should be adequate to support the proposed clinical trial.
- 4.2 Clinical trials should be scientifically sound and reflect the state of knowledge and experience with the investigational product(s), including, if applicable, the condition to be treated, diagnosed or prevented; the current understanding of the underlying biological mechanism (of both the condition and the treatment); and the population for which the investigational product is intended.
- 4.3 There should be periodic review of current scientific knowledge and approaches to determine whether modifications to the trial are needed, since new or unanticipated information may arise once the trial has begun.
- 5. Clinical trials should be designed and conducted by qualified individuals.**
- 5.1 Individuals with different expertise and training may be needed across all phases of a clinical trial, such as physicians, scientists, ethicists, technology experts, trial coordinators, monitors, auditors and statisticians. Individuals involved in a trial should be qualified by education, training and experience to perform their respective task(s).
- 6. Quality should be built into the scientific and operational design and conduct of clinical trials.**
- 6.1 Quality of a clinical trial is considered in this guideline as fit for purpose. The quality and amount of the information generated during a clinical trial should support good decision making.

- 6.2 Factors critical to the quality of the trial should be identified. These factors are attributes of a trial that are fundamental to the protection of participants, the reliability and interpretability of the trial results and the decisions made based on those trial results. Quality by design involves focusing on the design of all components of the trial in order to maximise the likelihood of trial success (i.e., that the trial will answer the research question).
- 6.3 Strategies should be implemented to avoid, detect and address serious non-compliance with GCP, the trial protocol and applicable regulatory requirements to prevent recurrence.

7. Clinical trial processes, measures and approaches should be implemented in a way that is proportionate to the risks to participants and to the importance of the data collected.

- 7.1 Trial processes should be proportionate to the risks inherent in the trial and the importance of the information collected. Risks in this context include risks to the rights, safety and well-being of trial participants as well as risks to the reliability of the trial results.
- 7.2 The focus should be on the risks to participants beyond those associated with standard medical care. The risks relating to investigational products that have a marketing authorisation when used in the clinical trial context may differ from the routine care of patients and should be taken into consideration.
- 7.3 Risks to critical to quality factors should be managed prospectively and adjusted when new or unanticipated issues arise once the trial has begun.

8. Clinical trials should be described in a clear, concise and operationally feasible protocol.

- 8.1 A well-designed trial protocol is fundamental to the protection of participants and for the generation of reliable results.
- 8.2 The scientific objectives of any trial should be clear and explicitly stated in the protocol.
- 8.3 The clinical trial protocol as well as the plans or documents for the protocol execution (e.g., statistical analysis plan, data management plan, monitoring plan) should be clear, concise and operationally feasible.

9. Clinical trials should generate reliable results.

- 9.1 The quality and amount of the information generated in a clinical trial should be sufficient to provide confidence in the trial's results and support good decision making.
- 9.2 Systems and processes that aid in data capture, management and analyses, as well as those that help ensure the quality of the information generated from the trial, should be fit for purpose, should capture the data required by the protocol and should be implemented in a way that is proportionate to the risks to participants and the importance of acquired data.

- 9.3 Trial processes should be operationally feasible and avoid unnecessary complexity, procedures and data collection. Trial processes should support the key trial objectives.
- 9.4 Computerised systems used in clinical trials should be fit for purpose, and factors critical to their quality should be addressed in their design or adaptation for clinical trial purposes.
- 9.5 Clinical trials should incorporate efficient and well-controlled processes for managing records through appropriate management of data integrity, traceability and protection of personal information, thereby allowing the accurate reporting, interpretation and verification of the clinical trial-related information.
- 9.6 Clinical trial-related records should be retained securely by sponsors and investigators for the required period of time and should be available to regulatory authorities upon request to enable reconstruction of the trial conduct and results in order to ensure the reliability of trial results.
- 9.7 The transparency of clinical trials in drug development includes registration on publicly accessible and recognised databases and the public posting of clinical trial results.

10. Roles and responsibilities in clinical trials should be clear and documented appropriately.

- 10.1 The sponsor may transfer or the investigator may delegate some or all their tasks, duties or functions (hereafter referred to as activities), but they retain overall responsibility for their respective activities.
- 10.2 Agreements should clearly define the roles, activities and responsibilities for the clinical trial and be documented appropriately. Where activities have been transferred or delegated to service providers, the responsibility for the conduct of the trial, including quality and integrity of the trial data, resides with the sponsor or investigator, respectively.
- 10.3 The sponsor or investigator should maintain appropriate oversight or supervision of the aforementioned activities, respectively.

11. Investigational products used in a clinical trial should be manufactured in accordance with applicable Good Manufacturing Practice (GMP) standards and be stored, shipped, handled and disposed of in accordance with the product specifications and the trial protocol.

- 11.1 Investigational products used in a clinical trial should be manufactured in accordance with applicable GMP standards.
- 11.2 Measures should be in place to ensure that the investigational product provided to trial participants retains its quality.
- 11.3 Investigational products should be used in accordance with the protocol and relevant trial documents.

11.4 Manufacturing, handling and labelling of investigational products should be undertaken in a manner that aligns with treatment assignment and maintains blinding, where applicable.

11.5 Investigational product labelling should follow applicable regulatory requirements.

11.6 Adequate measures to ensure that the investigational product is handled and shipped appropriately should be implemented.

III. ANNEX 1

1. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)

The IRB/IEC is responsible for the ethical review of the trial. The requirements for the IRB/IEC in this guideline should be read in conjunction with local regulatory requirements.

1.1 Responsibilities

1.1.1 The purpose of an IRB/IEC is to safeguard the rights, safety and well-being of all trial participants.

1.1.2 The IRB/IEC should review the following information, where applicable:

- (a) protocol and any amendments;
- (b) informed consent material(s), assent form(s), where applicable, and any updates, including the description of the process for how informed consent is to be obtained;
- (c) Investigator's Brochure or current scientific information, such as a basic product information brochure (e.g., Summary of Product Characteristics (SmPC), package leaflet or labelling), as appropriate, including their updates;
- (d) any other information to be provided to the trial participant(s), including a description of the media through which such information will be provided;
- (e) advertisement for participant recruitment (if used) and information on the recruitment process;
- (f) plans to compensate participants (if any);
- (g) ongoing updates to safety information (dependent on requirements of the IRB/IEC);
- (h) investigator's current curriculum vitae and/or other documentation evidencing qualifications;

(i) any other documents that the IRB/IEC may need to fulfil its responsibilities.

1.1.3 The IRB/IEC should review a proposed clinical trial within a reasonable time and document its reviews clearly identifying the trial, the documents reviewed and the dates for the following:

(a) approval/favourable opinion;

(b) modifications required prior to its approval/favourable opinion;

(c) disapproval/negative opinion;

(d) termination/suspension of any prior approval/favourable opinion.

1.1.4 The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk to participants.

1.1.5 The IRB/IEC may request more information than is outlined in section 2.8.11 be given to participants when, in the judgement of the IRB/IEC, the additional information would add meaningfully to the protection of the rights, safety and/or well-being of the participants.

1.1.6 Where the protocol indicates that prior consent of the trial participant or the participant's legally acceptable representative is not possible (see section 2.8.9), the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately address relevant ethical concerns and meet applicable regulatory requirements for such trials (e.g., in emergency situations).

1.1.7 If minors are to be included in a trial, the IRB/IEC should review the assent information considering the age, maturity and psychological state of the minor, as well as applicable regulatory requirements.

1.1.8 If the trial participants are compensated for their participation in the trial, the IRB/IEC should review both the amount and method of payment to participants to assure that neither presents problems of coercion or undue influence on the trial participants. Payments to a participant should be prorated and not wholly contingent on completion of the trial by the participant. Reasonable reimbursement of participants for travel and lodging is not typically coercive.

1.1.9 The IRB/IEC should ensure that information regarding payment to participants, including the methods, amounts and schedule of payment to trial participants, is set forth in the informed consent material and any other information to be provided to participants.

1.2 Composition, Functions and Operations

1.2.1 The IRB/IEC should consist of a reasonable number of members who collectively have the qualifications and experience to review and evaluate the science, medical aspects and ethics of the proposed trial. It is recommended that the IRB/IEC should include:

- (a) at least five members;
- (b) at least one member whose primary area of interest is not in medical sciences;
- (c) at least one member who is independent of the institution/investigator site.

Only those IRB/IEC members who are independent of the investigator and the sponsor of the trial should vote/provide an opinion. A list of IRB/IEC members and their qualifications should be maintained.

1.2.2 The IRB/IEC should perform its functions according to documented operating procedures, should maintain records of its activities and minutes of its meetings, and should comply with GCP and with the applicable regulatory requirement(s).

1.2.3 An IRB/IEC should make its decisions at announced meetings at which at least a quorum, as stipulated in its documented operating procedures, is present.

1.2.4 Only members who participate in the IRB/IEC review and discussion should vote/provide their opinion and/or advise.

1.2.5 The investigator, investigator site staff and/or sponsor, where appropriate, may provide information on any aspect of the trial but should not participate in the decision making of the IRB/IEC or in the vote/opinion of the IRB/IEC.

1.2.6 An IRB/IEC may invite non-members with expertise in special areas for assistance.

1.3 Procedures

The IRB/IEC should establish, document in writing or electronically, and follow its procedures, which should include:

1.3.1 Determining its composition (names and qualifications of the members) and the authority under which it is established;

1.3.2 Scheduling, notifying its members of and conducting its meetings;

1.3.3 Conducting initial and continuing review of trials;

1.3.4 Determining the frequency of continuing review, as appropriate;

- 388 1.3.5 Providing, according to the applicable regulatory requirements, expedited review and
 389 approval/favourable opinion of minor change(s) in ongoing trials that have the
 390 approval/favourable opinion of the IRB/IEC;
 391
- 392 1.3.6 Specifying that no participant should be admitted to a trial before the IRB/IEC issues
 393 its documented approval/favourable opinion of the trial;
 394
- 395 1.3.7 Specifying that no deviations from the protocol should be initiated without prior
 396 documented IRB/IEC approval/favourable opinion, except when necessary to
 397 eliminate immediate hazards to the participants;
 398
- 399 1.3.8 Specifying that the investigator/institution should promptly report to the IRB/IEC (see
 400 section 1.5):
 401
- 402 (a) deviations from the protocol to eliminate immediate hazards to the trial
 403 participants (see sections 1.3.7, 2.5.3 and 2.5.4);
 404
 - 405 (b) changes increasing the risk to participants and/or significantly affecting the
 406 conduct of the trial (see section 2.4.6);
 407
 - 408 (c) all suspected unexpected serious adverse reactions (SUSARs) in line with
 409 applicable regulatory requirements;
 410
 - 411 (d) new information that may affect adversely the safety of the participants or the
 412 conduct of the trial.
 413
- 414 1.3.9 Ensuring that the IRB/IEC (see section 1.5) promptly notifies in writing or
 415 electronically the investigator/institution or sponsor concerning:
 416
- 417 (a) its trial-related decisions/opinions;
 418
 - 419 (b) the reasons for its decisions/opinions;
 420
 - 421 (c) procedures for appeal of its decisions/opinions.
 422
- 422 **1.4 Records**
- 423 1.4.1 The IRB/IEC should retain all relevant records (e.g., documented procedures,
 424 membership lists, lists of occupations/affiliations of members, submitted documents,
 425 minutes of meetings and correspondence) in accordance with applicable regulatory
 426 requirements and make them available upon request from the regulatory
 427 authority(ies).
 428
- 429 1.4.2 The IRB/IEC may be asked by investigators, sponsors or regulatory authorities to
 430 provide its documented procedures and membership lists.

1.5 Submission and Communication

For the submission to or communication with the IRB/IEC, it is recognised that in most regions, there is also a requirement to make a submission to the relevant regulatory authority, and these may be combined, in line with applicable regulatory requirements, in a single submission in some regions. In addition, applicable regulatory requirements may require that submissions to the IRB/IEC are made in some regions by the investigator/institution and in others by the sponsor.

2. INVESTIGATOR

2.1 Qualifications and Training

2.1.1 The investigator(s) should be qualified by education, training and experience to assume responsibility for the proper conduct of the trial and should provide evidence of such qualifications.

2.1.2 The investigator should be familiar with the appropriate use of the investigational product(s) as described in the protocol, in the current Investigator's Brochure, in the product information and/or in other information sources provided by the sponsor.

2.2 Resources

2.2.1 The investigator should be able to demonstrate (e.g., based on retrospective or currently available data) a potential for recruiting the proposed number of eligible participants within the recruitment period as agreed with the sponsor.

2.2.2 The investigator should have sufficient time, an adequate number of available and qualified staff, and adequate facilities for the foreseen duration of the trial to conduct the trial properly and safely.

2.3 Responsibilities

2.3.1 The investigator may delegate trial-specific activities to other persons or parties.

The investigator may be supported by the sponsor to identify a suitable service provider(s); however, the investigator retains the final decision on whether the service provider intended to support the investigator is appropriate based on information provided by the sponsor (see section 3.6.6).

The investigator retains the ultimate responsibility and maintains appropriate supervision of the persons or parties undertaking the activities delegated to ensure the rights, safety and well-being of the trial participants and data reliability.

2.3.2 The investigator should ensure that persons or parties to whom the investigator has delegated trial-specific activities are appropriately qualified and supervised and are adequately informed about the protocol, the investigational product(s) and their assigned trial activities (including activities conducted by staff provided by other parties, for example, home nurses arranged by the sponsor). Trial-related training to

persons assisting in the trial should correspond to what is necessary to enable them to fulfil their delegated trial activities that go beyond their usual training and experience.

2.3.3 The investigator should ensure a record is maintained of the persons and parties to whom the investigator has delegated significant trial-related activities. In situations where the clinical trial activities are performed in accordance with routine clinical care, delegation documentation may not be required.

2.3.4 Agreements made by the investigator/institution with service providers for trial-related activities should be documented.

2.3.5 The investigator/institution should permit monitoring and auditing by the sponsor and inspection by the appropriate regulatory authority(ies).

2.4 Communication with IRB/IEC

2.4.1 Submission to the IRB/IEC may be made by the investigator/institution or sponsor in accordance with applicable regulatory requirements (see section 1.5).

2.4.2 Before initiating a trial, the investigator/institution should have a documented and dated approval/favourable opinion from the IRB/IEC for the trial protocol, informed consent material, participant recruitment procedures (e.g., advertisements) and any other information to be provided to participants.

2.4.3 As part of the investigator's/institution's or sponsor's (in accordance with applicable regulatory requirements) submission to the IRB/IEC, a current copy of the Investigator's Brochure or basic product information brochure should be provided (see section A.1.1 of Appendix A. Investigator's Brochure). If the Investigator's Brochure is updated during the trial, the IRB/IEC should receive the current version in accordance with applicable regulatory requirements.

2.4.4 As the trial progresses, the investigator/institution or sponsor should provide any updates to the participant information according to applicable regulatory requirements.

2.4.5 The investigator or the sponsor should submit documented summaries of the trial status to the IRB/IEC in accordance with local regulatory requirements or upon request.

2.4.6 The investigator or the sponsor should promptly communicate to the IRB/IEC (see section 1.3.8) and, where applicable, the institution about any changes significantly affecting the conduct of the trial and/or increasing the risk to participants.

2.5 Compliance with Protocol

2.5.1 The investigator should comply with the protocol and GCP and applicable regulatory requirements. The investigator/institution should sign the protocol or an alternative contract to confirm agreement with the sponsor.

2.5.2 The investigator should document all protocol deviations and review deviations communicated to them by the sponsor. For important deviations, the investigator should explain the deviation and implement appropriate measures to prevent a recurrence, where applicable, see section 3.9.3.

2.5.3 The investigator should follow the protocol and deviate only where necessary to eliminate an immediate hazard(s) to trial participants. In case of deviations undertaken to eliminate immediate hazard to trial participants, the investigator should inform the sponsor, IRB/IEC and/or regulatory authorities promptly.

2.5.4 The investigator should report information on the immediate hazard, the implemented change and the subsequent proposed protocol amendment to the IRB/IEC and/or regulatory authorities.

2.6 Premature Termination or Suspension of a Trial

2.6.1 If the trial is prematurely terminated or suspended for any reason, the investigator/institution should promptly inform the trial participants and should assure appropriate therapy and follow-up for the participants.

2.6.2 Where the investigator terminates or suspends their involvement in a trial without prior agreement by the sponsor, the investigator should promptly inform the sponsor, the IRB/IEC and the regulatory authorities in accordance with applicable regulatory requirements and should provide a detailed explanation of the reasons.

2.6.3 If the sponsor terminates or suspends a trial, the investigator/institution, or the sponsor, in accordance with applicable regulatory requirement(s), should promptly inform the IRB/IEC and the regulatory authorities. See section 3.17.1.

2.6.4 If the IRB/IEC terminates or suspends its approval/favourable opinion of a trial (see sections 1.1.3 and 1.3.9), the investigator should inform the institution, where applicable, and the investigator/institution should promptly notify the sponsor.

2.7 Participant Medical Care and Safety Reporting

2.7.1 Medical Care of Trial Participants

(a) A qualified physician or, where appropriate, a qualified dentist (or other qualified healthcare professionals in accordance with local regulatory requirements) who is an investigator or a sub-investigator for the trial should have the overall responsibility for trial-related medical care and decisions.

(b) Other appropriately qualified healthcare professionals may be involved in the medical care of trial participants, in line with their normal activities and in accordance with local regulatory requirements.

(c) During and following participation in a trial, the investigator/institution should ensure that adequate medical care is provided to a participant for any adverse events, including clinically significant laboratory values, related to the trial.

The investigator/institution should inform a participant when medical care is needed for intercurrent illness(es) of which the investigator becomes aware.

- (d) The investigator should inform the participant's primary physician about the participant's involvement in the trial if the participant has a primary physician and agrees to the primary physician being informed.

2.7.2 *Safety Reporting*

- (a) Adverse events and/or laboratory abnormalities required for safety evaluations (as outlined in the protocol) should be reported to the sponsor according to the reporting requirements and within the time periods specified in the protocol.
- (b) All serious adverse events (SAEs) should be reported immediately (after the investigator reasonably becomes aware of the event) to the sponsor. In accordance with applicable regulatory requirements, the protocol may identify SAEs not requiring immediate reporting, for example, deaths or other events that are endpoints. Subsequent information should be submitted as a follow-up report, as necessary.
- (c) For reported deaths, the investigator should supply the sponsor, the IRB/IEC and, where applicable, the regulatory authority with any additional requested information (e.g., autopsy reports and terminal medical reports) when they become available.
- (d) The investigator may delegate activities for safety reporting to qualified investigator site staff but retains the overall responsibility for safety of participants under their responsibility and compliance with the reporting requirements.

2.8 **Informed Consent of Trial Participants**

2.8.1 In obtaining and documenting informed consent (paper or electronic format), the investigator should comply with the applicable regulatory requirement(s) and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki. See the glossary term "informed consent." The informed consent process should include the following:

- (a) Prior to consenting and enrolling participants, the investigator should have the IRB/IEC's documented approval/favourable opinion of the informed consent materials and process;
- (b) The information should be as clear and concise as possible, use simple language and avoid unnecessary volume and complexity. This is to ensure that the trial participants or their legally acceptable representatives have an adequate understanding of the objectives of the trial, alternative treatments, the potential benefits and risks, burdens and their rights and obligations to be able to make an informed decision as to their participation in the trial;

(c) Varied approaches (e.g., text, images, videos and other interactive methods) may be used in the informed consent process including for providing information to the participant. Obtaining consent remotely may be considered where appropriate.

2.8.2 The participant or the participant's legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the participant's willingness to continue trial participation. The communication of this information and confirmation of the willingness to continue trial participation should be documented.

New information that could impact a participant's willingness to continue participation should be assessed to determine if re-consent is needed (e.g., depending on the stage of the trial, consideration should be given to whether the new information is relevant only to new participants or to existing participants). If re-consent is needed (e.g., information on emerging safety concerns), new information should be clearly identified in the revised informed consent materials. Revised informed consent materials should receive the IRB/IEC's approval/favourable opinion in advance of use.

2.8.3 Neither the investigator nor the investigator site staff should coerce or unduly influence a participant to participate or to continue their participation in the trial.

2.8.4 None of the information provided to the participant during the informed consent process should contain any language that causes the participant or the participant's legally acceptable representative to waive or to appear to waive any legal rights, or that releases or appears to release the investigator, the institution, the sponsor or their service providers from liability for negligence.

2.8.5 The informed consent process should be conducted by the investigator or other investigator site staff delegated by the investigator, in accordance with applicable regulatory requirements. If the participant is unable to provide consent themselves, the participant's legally acceptable representative should provide their consent on behalf of the participant.

2.8.6 The information provided during the informed consent process and translations should be relevant, clear, simple, concise and understandable to the participant or the participant's legally acceptable representative and the impartial witness, where applicable.

2.8.7 Before informed consent may be obtained, the investigator or investigator site staff delegated by the investigator, in accordance with the protocol and conditions of IRB/IEC favourable opinions/approvals, should provide the participant or the participant's legally acceptable representative ample time unless justified (e.g., in an emergency situation) and opportunity to enquire about trial details and to decide whether or not to participate in the trial. Questions about the trial should be answered

to the satisfaction of the participant or the participant's legally acceptable representative.

2.8.8 Prior to trial participation, the informed consent form should be signed and dated by the participant or by the participant's legally acceptable representative and, where appropriate, impartial witness and by the investigator or delegated investigator site staff who conducted the informed consent discussion. The informed consent process may involve a physical signature or an electronic signature.

2.8.9 In emergency situations, when prior consent of the participant is not possible, the consent of the participant's legally acceptable representative, if present, should be requested. When prior consent of the participant is not possible and the participant's legally acceptable representative is not available, enrolment of the participant should require measures described in the protocol and/or elsewhere, with documented approval/favourable opinion by the IRB/IEC, to protect the participant's rights, safety and well-being and to ensure compliance with applicable regulatory requirements. The participant or the participant's legally acceptable representative should be informed about the trial as soon as possible, and consent as appropriate (see section 2.8.10) should be requested.

2.8.10 If a participant or the legally acceptable representative is unable to read, an impartial witness should be present (remotely or in-person) during the entire informed consent discussion. After the informed consent form and any other information is read and explained to the participant or the participant's legally acceptable representative and they have orally consented to the participant's trial participation and, if capable of doing so, have signed and personally dated the informed consent form, the witness should contemporaneously sign and personally date the consent form. By signing the consent form, the witness attests that the consent information was accurately explained to and apparently understood by the participant or the participant's legally acceptable representative and that informed consent was freely given by the participant or the participant's legally acceptable representative.

2.8.11 The informed consent discussion and the informed consent materials to be provided to participants should explain the following as applicable:

- (a) the purpose of the trial;
- (b) that the trial involves research and summary of the experimental aspects of the trial;
- (c) the trial's investigational product(s) and the probability for random assignment to the investigational product, if applicable;
- (d) the trial procedures to be followed including all invasive procedures;
- (e) the participant's obligations;

- (f) the reasonably foreseeable risks or inconveniences to the participant and, when applicable, the participant's partner, to an embryo, foetus or nursing infant;
- (g) the reasonably expected benefits. When there is no intended clinical benefit to the participant, the participant should be made aware of this;
- (h) the alternative procedure(s) or course(s) of treatment that may be available to the participant and their important potential benefits and risks;
- (i) the compensation and/or treatment available to the participant in the event of trial-related injury;
- (j) any anticipated prorated compensation to the participant for trial participation;
- (k) any anticipated expenses to the participant for trial participation;
- (l) that the participant's trial participation is voluntary, and the participant may refuse to participate or may withdraw, at any time, without penalty or loss of benefits to which the participant is otherwise entitled;
- (m) the process by which the participant's data will be handled, including in the event of the withdrawal of participation in accordance with regulatory requirements;
- (n) that by agreeing to participate in the trial, the participant or their legally acceptable representative allows direct access to original medical records, per applicable regulatory requirements, while safeguarding the confidentiality of the participant. This access is limited for the purpose of reviewing trial activities and/or reviewing or verifying data and records by the IRB/IEC(s), regulatory authority(ies) and the sponsor's representatives, for example, monitor(s) or auditor(s);
- (o) that records identifying the participant will be kept confidential and, to the extent permitted by the applicable regulatory requirements, will not be made publicly available. If the trial results are published, the participant's identity will remain confidential. The trial may be registered on publicly accessible and recognised databases, per applicable regulatory requirements;
- (p) that the participant or the participant's legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to the participant's willingness to continue trial participation;
- (q) the person(s) to contact for further trial information and the trial participant's rights, and whom to contact in the event of suspected trial-related injury;

- (r) the foreseeable circumstances and/or reasons under which the participant's trial participation may be terminated;
- (s) the expected duration of the participant's trial participation;
- (t) the approximate number of participants involved in the trial;
- (u) that trial results and information on the participant's actual treatment, if appropriate, will be made available to them should they desire it.

2.8.12 Prior to participation, the participant or the participant's legally acceptable representative should receive a copy (paper or electronic) of the signed informed consent form and any other informed consent materials provided to the participants, or in accordance with applicable regulatory requirements. During trial participation, the participant or the participant's legally acceptable representative should receive a copy of the consent form updates and any other updated informed consent materials provided to participants.

2.8.13 Where a minor is to be included as a participant, age-appropriate assent information should be provided and discussed with the minor as part of the consent process, and assent from the minor to enrol in the trial should be obtained as appropriate. A process for re-consent should be considered if, during the course of the trial, the minor reaches the age of legal consent, in accordance with applicable regulatory requirements.

2.8.14 When a clinical trial includes participants who may only be enrolled in the trial with the consent of the participant's legally acceptable representative (e.g., minors, patients with severe impaired decision-making capacity), the participant should be informed about the trial to the extent compatible with the participant's understanding and, if capable, the participant should sign and personally date the informed consent form or assent form as appropriate.

2.8.15 In exceptional circumstances (e.g., public health emergencies), when the usual methods to obtain and document informed consent are not possible, the use of alternative measures and technologies in accordance with local IRBs/IECs and applicable regulatory requirements should be considered.

2.9 End of Participation in a Clinical Trial

2.9.1 When a participant decides to stop treatment with the investigational product, stop trial visits or completely withdraw from a trial; is discontinued from the trial; or reaches routine end of trial, the investigator should follow the protocol and other sponsor instructions to determine appropriate follow-up measures. This may include instructions to avoid unnecessary loss of already collected critical data in accordance with applicable regulatory requirements.

2.9.2 Although a participant is not obliged to provide a reason(s) for withdrawing prematurely from a trial, the investigator should make a reasonable effort to ascertain

the reason(s), while fully respecting the participant's rights. The investigator should consider discussing with the participant or the participant's legally acceptable representative the reasons for withdrawal to determine if there are ways to address the concerns. The investigator site staff should make an effort to explain to the participant the value and importance of continuing their participation to minimise trial participants withdrawal.

- 2.9.3 Where relevant, the investigator should inform the participant about the trial results and treatment received when this information is available from the sponsor after unblinding, with due respect to the participant's preference to be informed.

2.10 Investigational Product Management

- 2.10.1 Responsibility for investigational product(s) accountability rests with the investigator/institution. The sponsor may facilitate this process.

- 2.10.2 When the investigator/institution assigns some or all of their activities for investigational product(s) accountability to a pharmacist or another individual, they should be under the supervision of the investigator/institution.

- 2.10.3 The investigator/institution and/or a pharmacist or other appropriate individual should maintain records of the product's delivery, the inventory, the use by each participant (including documenting that the participants were provided the doses specified by the protocol) and the return to the sponsor and destruction or alternative disposition of unused product(s). These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable) and the unique code numbers assigned to the investigational product(s) and trial participants. For authorised medicinal products, alternative approaches to the aforementioned may be considered, in accordance with local regulatory requirements.

- 2.10.4 The investigational product(s) should be stored as specified by the sponsor and in accordance with applicable regulatory requirement(s).

- 2.10.5 The investigator should ensure that the investigational product(s) are used only in accordance with the approved protocol.

- 2.10.6 Where applicable, the investigator or a person designated by the investigator/institution should explain the correct use of the investigational product(s) to each participant and should check, at intervals appropriate for the trial, that each participant is following the instructions properly.

2.11 Randomisation Procedures and Unblinding

The investigator should follow the trial's randomisation procedures, if any, and, in the case of an investigator-blinded trial, should ensure that the identification code is broken only in accordance with the protocol. In the case of an emergency, to protect patient safety, the investigator should be prepared and capable from the start of the trial to perform unblinding without undue delay and hinderance. The investigator should promptly document and explain

to the sponsor any premature unblinding (e.g., accidental unblinding, emergency unblinding to protect trial participant, unblinding due to an SAE) of the investigational product(s).

2.12 Records

2.12.1 In generating, recording and reporting trial data, the investigator should ensure the integrity of data under their responsibility, irrespective of the media used.

2.12.2 The investigator/institution should maintain adequate source records that include pertinent observations on each of the trial participants under their responsibility. Source records should be attributable, legible, contemporaneous, original, accurate and complete. Changes to source records should be traceable, should not obscure the original entry and should be explained if necessary (via an audit trail). The investigator should define what is considered to be a source record(s), the methods of data capture and their location prior to starting the trial and should update this definition when needed. Unnecessary transcription steps in between the source record and the data acquisition tool should be avoided.

2.12.3 The investigator should have timely access to and be responsible for the timely review of data, including relevant data from external sources (e.g., central laboratory data, centrally read imaging data, other institution's records and, if appropriate, electronic patient-reported outcome (ePRO) data) which can have an impact on, for example, participant eligibility, treatment or safety. The protocol may provide exceptions for access, for instance, to protect blinding.

2.12.4 The investigator should ensure that data acquisition tools and other systems deployed by the sponsor for clinical trial purposes are used as specified in the protocol or trial-related instructions.

2.12.5 The investigator should ensure the accuracy, completeness, legibility and timeliness of the data reported to the sponsor in the data acquisition tools completed by the investigator site (e.g., case report form (CRF)) and in all required reports. The investigator should review and endorse the reported data at milestones agreed upon with the sponsor (e.g., interim analysis).

2.12.6 Data reported to the sponsor should be consistent with the source records or the discrepancies explained. Changes or corrections in the reported data should be traceable, should be explained (if necessary) and should not obscure the original entry.

2.12.7 The investigator/institution should implement appropriate measures to protect the privacy and confidentiality of personal information of trial participants in accordance with applicable regulatory requirements on personal data protection. Data reported to the sponsor should be identified by an unambiguous participant code that can be traced back to the identity of the participant by the investigator/institution.

2.12.8 For systems deployed by the investigator/institution that maintain and retain trial data/information, the investigator/institution should ensure that such data are

protected from unauthorised access, disclosure, dissemination or alteration and from inappropriate destruction or accidental loss.

2.12.9 When using computerised systems in a clinical trial, the investigator/institution should do the following:

- (a) for systems deployed by the investigator/institution, ensure that appropriate individuals have secure and attributable access;
- (b) for systems deployed by the investigator/institution specifically for the purposes of clinical trials, ensure that the requirements for computerised systems in section 4 are addressed;
- (c) where equipment for data acquisition is provided to trial participants by the investigator, ensure that traceability is maintained and participants are provided with appropriate training;
- (d) ensure that incidents in the use and operation of computerised systems, which in their judgement may have a significant and/or persistent impact on the trial data, are reported to the sponsor and, where applicable, to the IRB/IEC.

2.12.10 The investigator/institution should maintain the trial records as specified in Appendix C. Essential Records for the Conduct of a Clinical Trial and as required by the applicable regulatory requirement(s). The investigator/institution should have control of all essential records generated by the investigator/institution before, during and after the trial. The investigator/institution should take measures to prevent accidental or premature destruction of these records. If the investigator closes a site or leaves a site during or after the end of the clinical trial, the sponsor should be notified of the appropriate individual responsible for retention of the site's essential records.

2.12.11 The investigator/institution should retain the essential records for the required retention period in accordance with applicable regulatory requirements or until the sponsor informs the investigator/institution that these records are no longer needed, whichever is the longer (see Appendix C).

2.12.12 Upon request of the monitor, auditor, IRB/IEC or regulatory authority, the investigator/institution should make available for direct access all requested trial-related records.

2.13 Clinical Trial/Study Reports

2.13.1 Upon completion of the trial, the investigator, where applicable, should inform the institution. The investigator/institution should provide the IRB/IEC with a summary of the trial's outcome and, if applicable, the regulatory authority(ies) with any required reports.

2.13.2 Where a coordinating investigator is involved in a trial, consideration should be given to them being a signatory on the clinical trial report; see ICH E3 Structure and Content of Clinical Study Reports.

3. SPONSOR

The responsibility of the sponsor entails the implementation of risk-proportionate processes to ensure the safety of the trial participants and the reliability of the trial results throughout the clinical trial life cycle.

3.1 Trial Design

3.1.1 When planning trials, the sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials and/or real-world data are available to support human exposure by the route, at the dosages, for the duration and in the trial population to be studied.

3.1.2 Sponsors should incorporate quality into the design of the clinical trial by identifying factors that are critical to the quality of the trial and by managing risks to those factors.

3.1.3 Sponsors should consider inputs from a wide variety of stakeholders, for example, healthcare professionals and patients, to support the development plan and clinical trial protocols as described in ICH E8(R1) and when developing the informed consent material and any other participant-facing information.

3.1.4 The sponsor should ensure that all aspects of the trial are operationally feasible and should avoid unnecessary complexity, procedures and data collection. Protocols, data acquisition tools and other operational documents should be fit for purpose, clear, concise and consistent, when applicable.

3.2 Resources

The sponsor should ensure that sufficient resources are available to appropriately conduct the trial.

3.3 Allocation of Activities

Prior to initiating clinical trial activities, the sponsor should determine the roles and allocate trial-related activities accordingly.

3.4 Qualification and Training

The sponsor should utilise appropriately qualified individuals for the activities to which they are assigned (e.g., biostatisticians, clinical pharmacologists, physicians, data scientists/data managers, auditors and monitors) throughout the trial process.

3.4.1 Medical Expertise

The sponsor should have medical personnel readily available who will be able to advise on specific trial-related medical questions or problems.

3.5 Financing

The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator/institution.

3.6 Agreements

3.6.1 Agreements made by the sponsor with the investigator/institution, service providers and any other parties (e.g., independent data monitoring committee (IDMC), adjudication committee) involved with the clinical trial should be documented prior to initiating the activities.

3.6.2 Agreements should be updated when necessary to reflect significant changes in the activities delegated.

3.6.3 The sponsor should obtain the investigator's/institution's and, where applicable, service provider's agreement:

(a) to conduct the trial in accordance with the approved protocol and in compliance with GCP and applicable regulatory requirement(s);

(b) to comply with procedures for data recording/reporting;

(c) to retain the trial-related essential records for the required retention period in accordance with applicable regulatory requirements or until the sponsor informs the investigator/institution or, where applicable, the service provider, that these documents are no longer needed, whichever is longer;

(d) to permit monitoring, auditing and inspections by sponsors, IRB/IECs and regulatory authorities (domestic and foreign) including providing direct access to source records and facilities, including to those of service providers.

3.6.4 The responsibilities of coordinating investigator(s) and the other participating investigators should be documented prior to the start of the trial.

3.6.5 Any of the sponsor's trial-related activities that are transferred to and assumed by a service provider should be documented in an agreement. The sponsor's trial-related activities that are not specifically transferred to and assumed by a service provider are retained by the sponsor.

3.6.6 The sponsor should provide information to the investigator on any service provider identified by the sponsor to undertake any activities under the responsibility of the investigator. The responsibility for such activities remains with the investigator.

3.6.7 A sponsor may transfer any or all of the sponsor's trial-related activities to a service provider; however, the ultimate responsibility for the sponsor's trial-related activities, including protection of participants' rights, safety and well-being and reliability of the trial data, resides with the sponsor. Any service provider used for clinical trial

activities should implement appropriate quality management and report to the sponsor any incidents that might have an impact on the safety of trial participants or/and trial results.

3.6.8 The sponsor is responsible for assessing the suitability of and selecting the service provider to ensure that they can adequately undertake the activities transferred to them. The sponsor should provide the service providers with the protocol where necessary as well as any other documents required for them to perform their activities.

3.6.9 The sponsor should have access to relevant information (e.g., SOPs and performance metrics) for selection and oversight of service providers.

3.6.10 The sponsor should ensure appropriate oversight of important trial-related activities that are transferred to service providers and further subcontracted.

3.6.11 Trial-related activities performed by service providers should be conducted in accordance with relevant GCP requirements, which may be fulfilled by a service provider's existing processes.

3.6.12 A clinical trial may have one or several sponsors where permitted under applicable regulatory requirements. In trials with more than one sponsor, the sponsors should have a documented agreement that sets out their respective responsibilities, in accordance with local regulatory requirements and/or practice. Where the documented agreement does not specify to which sponsor a given responsibility is attributed, that responsibility lies with all sponsors.

3.7 Investigator Selection

3.7.1 The sponsor is responsible for selecting the investigator(s)/institution(s). Each investigator should be qualified by education, training and experience and should demonstrate they have adequate resources and facilities to properly conduct the trial. If organisation of a coordinating committee and/or selection of coordinating investigator(s) are to be utilised in multicentre trials, their organisation and/or selection are the sponsor's responsibility, and their roles should be documented prior to their involvement in the trial.

3.7.2 The sponsor should provide the investigator(s)/institution(s) with the protocol and an up-to-date Investigator's Brochure as well as sufficient time for the review of the protocol and the information provided.

3.8 Communication with IRB/IEC and Regulatory Authority(ies)

3.8.1 Notification/Submission to Regulatory Authority(ies)

In accordance with applicable regulatory requirement(s), before initiating the clinical trial(s), the sponsor (or the sponsor and the investigator) should submit any required application(s) to the appropriate regulatory authority(ies) for review, acceptance and/or permission to begin the trial(s). Any notification/submission should be dated and contain sufficient information to identify the protocol.

1046 3.8.2 *Confirmation of Review by IRB/IEC*

1047 (a) Where reference is made to a submission to the IRB/IEC, this can be made by
1048 the investigator/institution or sponsor in accordance with applicable regulatory
1049 requirements (see section 1.5).

1050
1051 (b) The sponsor should ensure that the following is obtained:

1052
1053 (i) The name and address of the relevant IRB/IEC along with:

1054
1055 (aa) a statement that it is organised and operates according to GCP
1056 and the applicable regulatory requirements;

1057
1058 (bb) documented initial and subsequent IRB/IEC
1059 approval/favourable opinion as well as any termination of the
1060 trial or the suspension of approval/favourable opinion.

1061 **3.9 Sponsor Oversight**

1062 3.9.1 The sponsor should ensure that the trial design and trial conduct, the processes
1063 undertaken, and the information and data generated are of sufficient quality to ensure
1064 reliable trial results, trial participant's safety and appropriate decision making.

1065
1066 3.9.2 The sponsor should ensure that trial processes are conducted in compliance with the
1067 trial protocol and related documents as well as with applicable regulatory
1068 requirements and ethical standards.

1069
1070 3.9.3 The sponsor should determine necessary trial-specific criteria for classifying protocol
1071 deviations as important (i.e., those that impact the rights, safety and well-being of trial
1072 participants and the reliability of results).

1073
1074 3.9.4 Decisions related to the trial should be appropriately assessed for their impact on
1075 participant's rights, safety and well-being and the reliability of trial results. Risks
1076 related to such decisions should be suitably managed throughout the planning,
1077 conduct and reporting of the trial.

1078
1079 3.9.5 The range and extent of oversight measures should be fit for purpose and tailored to
1080 the complexity of and risks associated with the trial. The selection and oversight of
1081 investigators and service providers are fundamental features of the oversight process.
1082 Oversight by the sponsor includes quality assurance and quality control processes
1083 relating to the trial-related activities of investigators and service providers.

1084
1085 3.9.6 The sponsor should ensure appropriate and timely escalation and follow-up of issues
1086 to allow the implementation of appropriate actions in a timely manner.

1087
1088 3.9.7 The sponsor may consider establishing an IDMC to assess the progress of a clinical
1089 trial including the safety data and the efficacy endpoints at intervals and to recommend
1090 to the sponsor whether to continue, modify or stop a trial.

3.9.8 Where appropriate, sponsors may also establish an endpoint assessment/adjudication committee in certain trials to review important endpoints reported by investigators to determine whether the endpoints meet protocol-specified criteria. Such committees should typically be blinded to the assigned treatments when performing their assessments, regardless of whether the trial itself is conducted in a blinded manner, to ensure that the data reviewed by committee are as free of bias as possible.

3.9.9 Committees established for purposes that could impact participant safety or the reliability of trial results should include members with relevant expertise and with managed conflicts of interest, have written operating procedures (e.g., charters) and document their decisions.

3.10 Quality Management

The sponsor should implement an appropriate system to manage quality throughout all stages of the trial process. Quality management includes the design and implementation of efficient clinical trial protocols including tools and procedures for trial conduct (including for data collection and management) in order to support participant's rights, safety and well-being and the reliability of trial results. The sponsor should adopt a proportionate and risk-based approach to quality management, which involves incorporating quality into the design of the clinical trial (i.e., quality by design) and identifying those factors that are likely to have a meaningful impact on participant's rights, safety and well-being and the reliability of the results (i.e., critical to quality factors as described in ICH E8(R1)). The sponsor should describe the quality management approach implemented in the trial in the clinical trial report (see ICH E3).

3.10.1 Risk Management

A proportionate approach to the identification and management of risk is described below:

3.10.1.1 Risk Identification

The sponsor should identify risks that may have a meaningful impact on critical to quality factors. Risks should be considered across the processes used in the clinical trial (e.g., patient selection, informed consent process, randomisation and investigational product administration, data handling, and service provider activities).

3.10.1.2 Risk Evaluation

The sponsor should evaluate potential risks by considering:

- (a) the likelihood of harm/hazard occurring;
- (b) the extent to which such harm/hazard would be detectable;
- (c) the impact of such harm/hazard on trial participant protection and the reliability of trial results.

3.10.1.3 Risk Control

- (a) Risk control should be proportionate to the importance of the risk to participants' rights, safety and well-being and the reliability of trial results.

1131 Risk mitigation activities may be incorporated in protocol design and
1132 implementation, monitoring plans, agreements between parties defining roles
1133 and responsibilities, systematic safeguards to ensure adherence to SOPs, and
1134 training in processes and procedures.

1135
1136 (b) The sponsor should set acceptable ranges to support this process within which
1137 variation can be accepted. Where deviation beyond these ranges is detected,
1138 an evaluation should be performed to determine if there is a possible systemic
1139 issue and if action is needed.

1140 3.10.1.4 Risk Communication

1141 The sponsor should communicate the identified risks and mitigating activities, if
1142 applicable, to those who are involved in taking action or are affected by such activities.
1143 Communication also facilitates risk review and continual improvement during clinical
1144 trial conduct.

1145 3.10.1.5 Risk Review

1146 The sponsor should periodically review risk control measures to ascertain whether the
1147 implemented quality management activities remain effective and relevant, taking into
1148 account emerging knowledge and experience.

1149 3.10.1.6 Risk Reporting

1150 The sponsor should summarise and report the risks and the remedial actions taken in
1151 relation to important deviations from the acceptable ranges as detailed in section
1152 3.10.1.3(b) and document them in the clinical trial report (ICH E3).

1153 3.11 Quality Assurance and Quality Control

1154 The sponsor is responsible for establishing, implementing and maintaining
1155 appropriate quality assurance and quality control processes and documented
1156 procedures to ensure that trials are conducted and data are generated, recorded and
1157 reported in compliance with the protocol, GCP and the applicable regulatory
1158 requirement(s).

1159 3.11.1 Quality Assurance

1160 Quality assurance should be applied throughout the clinical trial and includes
1161 implementing strategies to identify potential or actual causes of serious non-
1162 compliance with the protocol, GCP and/or applicable regulatory requirements to
1163 enable their corrective and/or preventive actions.

1164 3.11.2 Audit

1165 When performed, audits should be conducted in a manner that is proportionate to the
1166 risks associated with the conduct of the trial.

1167 The purpose of a sponsor's audit, which is independent of and separate from routine
1168 monitoring or quality control functions, is to evaluate whether the processes put in
1169 place to manage and conduct the trial are effective and compliant.

1170 3.11.2.1 *Selection and Qualification of Auditors*

1171 (a) The sponsor should appoint individuals who are independent of the clinical
1172 trial being audited.

1173
1174 (b) The sponsor should ensure that the auditors are qualified by training and
1175 experience to conduct audits properly.

1176 3.11.2.2 *Auditing Procedures*

1177 (a) The sponsor should ensure that the auditing of clinical trials/processes is
1178 conducted in accordance with the sponsor's documented procedures on what
1179 to audit, how to audit (i.e., on-site or remote), the frequency of audits and the
1180 form and content of audit reports.

1181
1182 (b) The sponsor's audit plan, program and procedures for a trial audit should be
1183 guided by the importance of the trial to submissions to regulatory authorities,
1184 the number of participants in the trial, the type and complexity of the trial, the
1185 level of risks to the trial participants and any identified problem(s).

1186
1187 (c) The observations and findings of the auditor(s) should be documented.

1188
1189 (d) To preserve the independence and value of the audit function, the regulatory
1190 authority(ies) should not routinely request the audit reports. Regulatory
1191 authority(ies) may seek access to an audit report on a case-by-case basis when
1192 evidence of serious GCP non-compliance exists or in the course of legal
1193 proceedings.

1194
1195 (e) When required by applicable regulatory requirements, the sponsor should
1196 provide an audit certificate.

1197 3.11.3 *Quality Control*

1198 Quality control should be applied to each stage of the data handling to ensure that data
1199 are reliable and have been processed correctly. Within clinical trials, monitoring and
1200 data management processes are the main quality control activities.

1201
1202 The quality control of sites (other than investigator sites, such as centralised imaging
1203 reading facilities), including on site and/or centralised activities, may be undertaken
1204 and reported using a risk-based approach.

1205 3.11.4 *Monitoring*

1206 The aim of monitoring is to ensure the participants' rights, safety and well-being and
1207 the reliability of trial results as the trial progresses. Monitoring is one of the principal
1208 quality control activities.

1209 Monitoring involves a broad range of activities including, but not limited to,
1210 communication with investigator sites, verification of the investigator and investigator
1211 site staff qualifications and site resources, training and review of trial documents and

information using a range of approaches including source data review, source data verification, data analytics and visits to institutional facilities undertaking trial-related activities. Some of these monitoring activities may be conducted by different methods and persons with different roles. However, monitoring should be performed by persons not involved in the clinical conduct of the trial being monitored. The monitoring approach should consider the activities and services involved, including decentralised settings, and be included in the monitoring plan. Monitors and other trial staff should adhere to data protection and confidentiality requirements in accordance with applicable regulatory requirements, institution policy and established data security standards.

Monitoring activities may include site monitoring (performed on-site or remotely) and centralised monitoring, depending on the monitoring strategy and the design of the clinical trial.

The sponsor should determine the appropriate extent and nature of monitoring, based on identified risks. Factors such as the objective, purpose, design, complexity, blinding, number of trial participants, investigational product, current knowledge of the safety profile and endpoints of the trial should be considered.

3.11.4.1 Investigator Site Monitoring

(a) Monitoring may be performed in relation to the clinical trial activities at the investigator sites (e.g., including their pharmacies and local laboratories, as appropriate). The frequency of monitoring activities should also be determined based on identified risks. Monitoring activities and their frequency should be modified as appropriate using knowledge gained.

(b) This monitoring activity may be performed on-site or remotely depending on the nature of the activity and its objectives.

(c) Monitoring may include secure, remote, direct read-only access to source records, other data acquisition tools and essential record retention systems.

3.11.4.2 Centralised Monitoring

(a) Centralised monitoring is an evaluation of accumulated data, performed in a timely manner, by the sponsor's qualified and trained persons (e.g., medical monitor, data scientist/data manager, biostatistician).

(b) Centralised monitoring processes provide additional monitoring capabilities that can complement and reduce the extent and/or frequency of site monitoring or be used on its own. Use of centralised data analytics can help identify systemic or site-specific issues, including protocol non-compliance and potentially unreliable data.

(c) Centralised monitoring may support the selection of sites and/or processes for targeted site monitoring.

1254 3.11.4.3 *Monitoring Plan*

1255 The sponsor should develop a monitoring plan that is tailored to the identified
 1256 potential safety risks, the risks to data quality and/or other risks to the reliability of
 1257 the trial results. Particular attention should be given to procedures relevant to
 1258 participant safety and to trial endpoints. The plan should describe the monitoring
 1259 strategy, the monitoring activities of all the parties involved, the various monitoring
 1260 methods and tools to be used, and the rationale for their use. The monitoring strategy
 1261 should ensure appropriate oversight of trial conduct and consider site capabilities and
 1262 the potential burden. The plan should focus on aspects that are critical to quality. The
 1263 monitoring plan should reference the sponsor's applicable policies and procedures.

1264 Monitoring of key data and processes (e.g., those related to primary endpoints and key
 1265 secondary endpoints and processes intended to assure patient safety) performed
 1266 outside the investigator site (e.g., central reading facilities, central laboratories) should
 1267 be addressed in the monitoring plan.

1268 3.11.4.4 *Monitoring Procedures*

1269 Persons performing monitoring should follow the sponsor's monitoring plan and
 1270 applicable monitoring procedures.

1271 3.11.4.5 *Monitoring Activities*

1272 Monitoring in accordance with the sponsor's requirements and monitoring plan
 1273 should generally include the following activities across the clinical trial life cycle, as
 1274 applicable.

1275 3.11.4.5.1 *Communication with Parties Conducting the Trial*

1276 (a) Establishing and maintaining a line of communication between the
 1277 sponsor and the investigator and other parties and individuals involved
 1278 in the trial conduct (e.g., centrally performed activities). In general, each
 1279 site should have an assigned monitor as their contact point.
 1280

1281 (b) Informing the investigator or other parties and individuals involved in
 1282 the trial conduct of identified deviations from the protocol, GCP and the
 1283 applicable regulatory requirements and taking appropriate action
 1284 designed to prevent recurrence of the detected deviations. Important
 1285 deviations should be highlighted and should be the focus of remediation
 1286 efforts as appropriate.
 1287

1288 (c) Informing the investigator or other parties and individuals involved in
 1289 the trial conduct of source record(s) or entry errors or omissions in data
 1290 acquisition tools and ensuring that corrections, additions or deletions are
 1291 made as appropriate, dated, explained (if necessary) and that approval
 1292 of the change is properly documented.
 1293

1294 (d) Actions taken in relation to the deviations, errors or omissions should be
 1295 proportionate to their importance.

3.11.4.5.2 *Investigator Site Selection, Initiation, Management and Close-out*

- (a) Selecting the site and confirming that the investigator and individuals or parties involved in the trial conduct have adequate qualifications, resources (see sections 3.1, 3.2, and 4.7) and facilities, including laboratories, equipment and investigator site staff, to safely and properly conduct the trial.
- (b) Confirming that the investigator, investigator site staff and other parties, and individuals involved in the trial conduct are adequately informed about the trial and follow the current approved protocol and other protocol-related documents, such as the current Investigator's Brochure and relevant information related to the investigational product and instructions related to their delegated activities.
- (c) Confirming that the investigator is maintaining the essential records (see Appendix C).
- (d) Confirming that informed consent was obtained before participation in the trial (see section 2.8) for all enrolled participants at the site.
- (e) Determining whether adverse events are appropriately reported within the time periods required by the protocol, GCP and the applicable regulatory requirement(s).
- (f) Clarifying the sponsor's protocol requirements for source records and the site's location of such data.
- (g) Verifying that the blinding is maintained, where applicable.
- (h) Reviewing and reporting the participant recruitment and retention rates.
- (i) Confirming that the investigator provides the required reports, notifications or other information in accordance with the protocol and trial procedures.
- (j) Confirming the arrangement for the retention of the essential records and the final accountability of the investigational product (e.g., return and destruction or alternative disposition, if appropriate) during site close-out activity.

3.11.4.5.3 *Monitoring of Investigational Product Management*

- (a) Confirming, for the investigational product(s):
 - (i) that storage conditions are acceptable and in accordance with the storage requirement specified in the protocol;

- (ii) that supplies are sufficient throughout the trial and are used within their shelf-life;
- (iii) that the correct investigational product(s) are supplied only to participants who are eligible to receive it at the protocol-specified dose(s) and, where appropriate, in accordance with the randomisation procedures;
- (iv) that the participants, investigator, investigator site staff and other relevant parties and individuals involved in the trial conduct are provided with necessary instruction on properly using, handling, storing, returning and destroying, or alternative disposition of the investigational product(s);
- (v) that the receipt, use, return and destruction, or alternative disposition of the investigational product(s) are controlled and documented adequately;
- (vi) that the disposition of unused investigational product(s) complies with applicable regulatory requirement(s) and is in accordance with the sponsor requirements;
- (vii) where product available on the market is dispensed and used in accordance with applicable regulatory requirements, some of the previously outlined considerations may not be applicable.

3.11.4.5.4 *Monitoring of Clinical Trial Data*

- (a) Verifying that the investigator is enrolling only eligible trial participants.
- (b) Checking the accuracy, completeness and consistency of the reported trial data against the source records and other trial-related records and whether these were reported in a timely manner. This can be done on the basis of using samples and supported by data analytics, as appropriate. The sample size may need adjustment based on previous monitoring results or other indications of insufficient data quality. Monitoring should:
 - (i) verify that the data required by the protocol and identified as critical in the monitoring plan are consistent with the source;
 - (ii) identify missing data, inconsistent data, data outliers, unexpected lack of variability and protocol deviations;
 - (iii) examine data trends, such as the range, consistency and variability of data within and across sites;

- (c) Identifying significant errors in data collection and reporting at a site or across sites, potential data manipulation and data integrity problems.

3.11.4.6 Monitoring Report

- (a) Reports of monitoring activities should include a summary of what was reviewed, a description of significant findings, conclusions and actions required to resolve them and follow-up on their resolution including those not resolved in previous reports. The requirements of monitoring reports (including their content and frequency) should be described in the sponsor's procedures.
- (b) Reports of investigator site and/or centralised monitoring should be provided to the appropriate sponsor staff as described in the sponsor's procedures in a timely manner for review and follow-up.
- (c) When needed, the report should describe findings requiring escalation for action and resolution. The sponsor should decide on the appropriate action to be taken, and these decisions and the resolution of the actions involved, where needed, should be recorded.

3.12 Noncompliance

- 3.12.1 Noncompliance with the protocol, SOPs, GCP and/or applicable regulatory requirement(s) by an investigator/institution or by member(s) of the sponsor's staff should lead to appropriate and proportionate action by the sponsor to secure compliance.
- 3.12.2 If noncompliance that significantly affects or has the potential to significantly affect trial participant's rights, safety or well-being or the reliability of trial results is discovered, the sponsor should perform a root cause analysis, implement appropriate corrective and preventive actions and confirm their adequacy unless otherwise justified. Where the sponsor identifies issues that could significantly impact participant's rights, safety and well-being or the reliability of trial results, the sponsor should notify the regulatory authority and/or IRB/IEC in line with applicable regulatory requirements.
- 3.12.3 If the monitoring and/or auditing identifies serious noncompliance on the part of an investigator/institution that persists despite efforts at remediation, the sponsor should terminate the investigator's/institution's participation in the trial. When an investigator's/institution's participation is terminated because of noncompliance, the sponsor should promptly notify the regulatory authority(ies) and IRB/IEC as appropriate.

3.13 Safety Assessment and Reporting

The sponsor is responsible for the ongoing safety evaluation of the investigational product(s).

1427 The Investigator's Brochure or, where applicable, the current scientific information such as a
1428 basic product information brochure, forms the basis of safety assessment and reporting for the
1429 clinical trial. For further information, see Appendix A.

1430 3.13.1 *Sponsor Review of Safety Information*

1431 The sponsor should aggregate, as appropriate, and periodically review relevant safety
1432 information. This may result in the update of the protocol, Investigator's Brochure,
1433 informed consent materials and related documents.

1434 The sponsor should review the available emerging safety information to assess
1435 whether there is any new data that may affect the participant's willingness to continue
1436 in the trial, impact the conduct of the trial, or alter the approval/favourable opinion of
1437 the IRB/IEC and/or regulatory authority(ies), as applicable. Any information of this
1438 nature should be communicated to the participants, investigator, IRB/IEC and
1439 regulatory authorities, as applicable, in a timely manner.

1440 3.13.2 *Safety Reporting*

1441 (a) The sponsor should submit to the regulatory authority(ies) safety updates and
1442 periodic reports, including changes to the Investigator's Brochure, as required
1443 by applicable regulatory requirements.

1444
1445 (b) The sponsor should, in accordance with the applicable regulatory
1446 requirement(s) and with ICH E2A Clinical Safety Data Management:
1447 Definitions and Standards for Expedited Reporting, expedite the reporting to
1448 the regulatory authority(ies) of all adverse drug reactions (ADRs) that meet
1449 three criteria: suspected, unexpected and serious (i.e., SUSARs).

1450
1451 (c) Safety reporting to regulatory authorities should be undertaken by assessing
1452 the expectedness of the reaction in relation to the applicable product
1453 information (e.g., the reference safety information (RSI) contained within the
1454 Investigator's Brochure or alternative documents) in accordance with
1455 applicable regulatory requirements. Refer to ICH E2F Development Safety
1456 Update Report for more information about RSI.

1457
1458 (d) The reporting of SUSARs to investigator(s)/institutions(s) and to the
1459 IRB(s)/IEC(s) should be undertaken in a manner that reflects the urgency of
1460 action required and should take into consideration the evolving knowledge of
1461 the safety profile of the product. Reporting of SUSARs to the
1462 investigators/institutions should be made in accordance with regulatory
1463 requirements. In some regions, periodic reporting of line listings with an
1464 overall safety assessment may be appropriate.

1465
1466 (e) Urgent safety issues requiring immediate attention or action should be
1467 reported to the IRB/IEC and/or regulatory authority(ies) and investigators
1468 without undue delay and as specified in regulatory requirements.

1469

1470 (f) Alternative arrangements for safety reporting to regulatory authorities,
 1471 IRBs/IECs, and investigators and for reporting by investigators to the sponsor
 1472 should be prospectively agreed upon with the regulatory authority(ies) and the
 1473 IRB/IEC if applicable, and described in the clinical trial protocol, (e.g., SAEs
 1474 considered efficacy or safety endpoints, which would not be subject to
 1475 unblinding and expedited reporting; see ICH E2A). See ICH E19.

1476 3.13.3 *Managing an Immediate Hazard*

1477 The sponsor should take prompt action to address immediate hazards to participants.
 1478 The sponsor should determine the causes of the hazard and based on this, take
 1479 appropriate remedial actions.

1480 The sponsor should consider whether the protocol requires amendment in response to
 1481 an immediate hazard. The information on the immediate hazard, if required, and any
 1482 subsequent protocol amendment should be submitted to the IRB/IEC and/or
 1483 regulatory authorities by the investigator/institution or sponsor (in accordance with
 1484 applicable regulatory requirements).

1485 3.14 **Insurance/Indemnification/Compensation to Participants and Investigators**

1486 3.14.1 If required by the applicable regulatory requirement(s), the sponsor should provide
 1487 insurance or should indemnify (legal and financial coverage) the investigator/the
 1488 institution against claims arising from the trial except for claims that arise from
 1489 malpractice and/or negligence.

1491 3.14.2 The sponsor's policies and procedures should address the costs of treatment of trial
 1492 participants in the event of trial-related injuries in accordance with the applicable
 1493 regulatory requirement(s).

1495 3.14.3 The approach to compensating trial participants should comply with applicable
 1496 regulatory requirement(s).

1497 3.15 **Investigational Product(s)**

1498 3.15.1 *Information on Investigational Product(s)*

1500 The sponsor should ensure that an Investigator's Brochure is developed and updated
 1501 as significant new information on the investigational product becomes available.
 1502 Alternatively, for authorised medicinal products, the sponsor should identify the basic
 1503 product information to be used in the trial (see Appendix A).

1504 3.15.2 *Manufacturing, Packaging, Labelling and Coding Investigational Product(s)*

1505 (a) The sponsor should ensure that the investigational product(s) (including active
 1506 control(s) and placebo, if applicable) is characterised as appropriate to the
 1507 stage of development of the product(s), is manufactured in accordance with
 1508 any applicable GMP and is coded and labelled in a manner that protects the
 1509 blinding, if applicable. In addition, the labelling should comply with
 1510 applicable regulatory requirement(s).

- (b) The sponsor should determine acceptable storage temperatures and other storage conditions (e.g., protection from light) for the investigational product(s), appropriate reconstitution fluids and procedures, and devices for product infusion, if any. The sponsor should inform all involved parties (e.g., monitors, investigators, pharmacists, storage managers) of these determinations.
- (c) The investigational product(s) should be packaged to prevent contamination and unacceptable deterioration during transport and storage.
- (d) In blinded trials, the sponsor should implement:
 - (i) a process to blind the sponsor staff, trial participant and/or investigator as appropriate to the investigational product identity and assignment to prevent and detect inappropriate unblinding;
 - (ii) a procedure and mechanism that permits the investigator to rapidly identify the product(s) in case of a medical emergency where unblinding is considered necessary, while protecting the identity of the treatment assignment of the other trial participants;
 - (iii) a mechanism that protects the blinding of the trial where a participant's treatment assignment is unblinded for the purpose of safety reporting to regulatory authorities and/or IRB/IEC, where appropriate.
- (e) If significant formulation changes are made in the investigational product(s) (including active control(s) and placebo, if applicable) during the course of clinical development, the results of any additional studies of the formulated product(s) (e.g., stability, dissolution rate, bioavailability) needed to assess whether these changes would significantly alter the pharmacokinetic profile of the product should be available prior to the use of the new formulation in clinical trials.

3.15.3 *Supplying and Handling Investigational Product(s)*

- (a) The sponsor is responsible for supplying the investigator(s)/institution(s) with the investigational product(s) or, where appropriate, supplying trial participants in accordance with applicable regulatory requirements and after obtaining the required approval/favourable opinion from the IRB/IEC and the regulatory authority(ies) for the trial.
- (b) The sponsor should ensure that instructions are available for the investigator/institution or trial participants on the handling and storage of investigational product(s). The procedures should consider adequate and safe receipt, handling, storage, dispensing, retrieval of unused product from participants and return of unused investigational product(s) to the sponsor (or

alternative disposition if authorised by the sponsor and in compliance with the applicable regulatory requirement(s)).

(c) The sponsor should:

- (i) ensure timely delivery of investigational product(s) to the investigator(s) or, where appropriate, to trial participants in accordance with applicable regulatory requirements to avoid any interruption to the trial as well as for the continuation of treatment for participants.
- (ii) maintain records that document the identity, shipment, receipt, return and destruction, or alternative disposition of the investigational product(s) (see Appendix C);
- (iii) maintain a system for retrieving investigational products and documenting this retrieval (e.g., for deficient product recall, return and destruction, or alternative disposition after trial completion, or expired product reclaim);
- (iv) maintain a system for the disposition of unused investigational product(s) and for the documentation of this disposition;
- (v) take steps to ensure that the investigational product(s) are stable over the period of use and only used within the current shelf-life;
- (vi) maintain sufficient quantities of the investigational product(s) used in the trials to reconfirm specifications should this become necessary and maintain records of batch sample analyses and characteristics. The samples should be retained either until the analyses of the trial data are complete or as required by the applicable regulatory requirement(s), whichever represents the longer retention period. The samples do not need to be kept by the sponsor in trials where an authorised medicinal product is used as an investigational product unmodified from its authorised state, since samples are kept by the manufacturer.

3.16 Data and Records

3.16.1 Data Handling

- (a) The sponsor should ensure the integrity and confidentiality of data generated and managed.
- (b) The sponsor should apply quality control to the relevant stages of data handling to ensure that the data are of sufficient quality to generate reliable results. The sponsor should focus their quality assurance and quality control activities and data review on critical data, including its relevant metadata.

- (c) The sponsor should pre-specify data to be collected and the method of its collection in the protocol (see Appendix B. Clinical Trial Protocol and Protocol Amendment(s)). Where necessary, additional details, including a data flow diagram, should be contained in a protocol-related document (e.g., a data management plan).
- (d) The sponsor should ensure that data acquisition tools are fit for purpose and designed to capture the information required by the protocol. They should be validated and ready for use prior to their required use in the trial.
- (e) The sponsor should ensure that documented processes are implemented to ensure the data integrity for the full data life cycle.
- (f) The sponsor should implement measures to ensure the safeguarding of the blinding, if any (e.g., maintain the blinding during data entry and processing).
- (g) The sponsor should provide guidance to investigators/institutions, service providers and trial participants, where relevant, on the expectations for data capture, data changes, data retention and data disposal.
- (h) The sponsor should not make changes to data entered by the investigator or trial participants unless justified and documented by the sponsor and agreed upon by the investigator.
- (i) The sponsor should allow correction of errors to data, including data entered by participants, where requested by the investigators/participants. Such data corrections should be justified and supported by source records around the time of original entry.
- (j) The sponsor should ensure that the investigator has access to data collected in accordance with the protocol during the course of the trial including relevant data from external sources, for example, central laboratory data, centrally read imaging data and, if appropriate, ePRO data that are necessary to enable the investigators to make decisions (e.g., on eligibility, treatment, continuing participation in the trial and care for the safety of the individual trial participants). The sponsor should pay special attention to data that may unblind the investigator and include the appropriate provisions in the protocol.
- (k) The sponsor should not have exclusive control of data captured in data acquisition tools.
- (l) The sponsor should ensure that the investigator has access to the required data for retention purposes.

- (m) The sponsor should ensure that the investigator receives instructions on how to navigate systems, data and relevant metadata for the trial participants under their responsibility.
- (n) The sponsor should seek investigator endorsement of their data at predetermined milestones.
- (o) The sponsor should document the data management steps to be undertaken prior to data analysis. These steps may vary depending on the purpose of the analysis to be conducted (e.g., data for IDMC, for interim analysis or the final analysis).
- (p) Prior to provision of the data for analysis, edit access to the data acquisition tools should be restricted as appropriate to the purpose of the analysis; for example, for interim analysis, the restriction may only be temporary or managed differently compared to the final analysis.
- (q) Deviations from the planned statistical analysis or changes made to the data analysis set after the trial has been unblinded (where applicable) should be clearly documented and justified and should only occur in exceptional circumstances (e.g., data discrepancies that must be resolved for the reliability of the trial results). Data changes should be authorised by the investigator and reflected in an audit trail. Post-unblinding data changes and deviations from the planned statistical analyses should be reported in the clinical trial report.
- (r) The sponsor should use an unambiguous trial participant identification code (see glossary term) that allows identification of all the data reported for each participant.
- (s) The sponsor should implement appropriate measures to protect the privacy and confidentiality of personal information of trial participants, in accordance with applicable regulatory requirements on personal data protection.
- (t) In accordance with applicable regulatory requirements, the sponsor should document what happens to data when a participant withdraws or discontinues from the trial.
- (u) The sponsor should ensure that trial data are protected from unauthorised access, disclosure, dissemination or alteration and from inappropriate destruction or accidental loss.
- (v) The sponsor should have processes and procedures in place for reporting incidents (including security breaches) that have a significant impact on the trial data to relevant parties, including regulatory authorities, where relevant.

- (w) When using computerised systems in a clinical trial, the sponsor should:
- (i) have a record of the computerised systems used in a clinical trial. This should include the use, functionality, interfaces and validation status of each computerised system, and who is responsible for its management should be described. The record should also include a description of implemented access controls and internal and external security measures;
 - (ii) ensure that the requirements for computerised systems deployed by the sponsor (e.g., requirements for validation, audit trails, user management, backup, disaster recovery and IT security) are addressed and implemented and that documented procedures and adequate training are in place to ensure the correct development, maintenance and use of computerised systems in clinical trials (see section 4). These requirements should be proportionate to the importance of the computerised system and the data or activities they are expected to process;
 - (iii) maintain a record of the individual users who are authorised to access the system, their roles and their access privileges;
 - (iv) ensure that access rights granted to investigator site staff are in accordance with delegations by the investigator and visible to the investigator;
 - (v) for systems deployed by the investigator/institution, assess whether such systems, if identified as containing source records in the trial, (e.g., electronic health records and other record keeping systems for source data collection and investigator site files) are fit for purpose or whether the known issue(s) can be appropriately mitigated. This assessment should occur during the process of selecting clinical trial sites and should be documented;
 - (vi) ensure that there is a process in place for service providers and investigators to inform the sponsor of system defects identified or incidents that could potentially constitute a serious non-compliance with the clinical trial protocol, trial procedures or GCP in accordance with section 3.13.

3.16.2 *Statistical Programming and Data Analysis*

This section concerning documentation of operational aspects of clinical trial statistical activities should be read in conjunction with ICH E9 Statistical Principles for Clinical Trials, which provides detailed guidance on statistical principles for clinical development, trial design, conduct, analysis and reporting.

- (a) The sponsor should ensure that appropriate and documented quality control of statistical programming and data analysis is implemented (e.g., for sample size calculations, results for IDMC, outputs for clinical trial report, statistical or centralised monitoring).
- (b) The sponsor should ensure the traceability of data transformations and derivations during data processing and analysis.
- (c) The sponsor should ensure that the allocation to or exclusion of each trial participant from any analysis set is predefined (e.g., in the protocol or the statistical analysis plan). The rationale for inclusion or exclusion for any participant (or particular data point) should be clearly described and documented.
- (d) Procedures should be in place to describe unblinding; these descriptions should include:
 - (i) who was unblinded, at what timepoint and for what purpose they were unblinded;
 - (ii) who should remain blinded;
 - (iii) the safeguards in place to preserve the blinding.
- (e) The sponsor should retain the statistical programming records that relate to the output contained or used in reports of the trial results, including quality control/validation activities performed. Outputs should be traceable to the statistical software programs, and they should be dated and time stamped and protected against any changes.

3.16.3 *Record Keeping and Retention*

- (a) The sponsor (or subsequent owners of the data) should retain all of the sponsor-specific essential records pertaining to the trial in conformance with the applicable regulatory requirement(s).
- (b) The sponsor should inform the investigator(s)/institution(s) and service providers, when appropriate, in writing of the need for essential records retention and should notify the investigator(s)/institution(s) and service providers, when appropriate, in writing when the trial-related records are no longer needed.

1773 (c) The sponsor should report any transfer of ownership of the essential records
1774 to the appropriate authority(ies) as required by the applicable regulatory
1775 requirement(s).

1776 3.16.4 *Record Access*

1777 (a) The sponsor should ensure that it is specified in the protocol or other
1778 documented agreement that the investigator(s)/institution(s) provide direct
1779 access to source records for trial-related monitoring, audits, IRB/IEC review
1780 and regulatory inspection.

1781
1782 (b) The sponsor should ensure that trial participants have consented to direct
1783 access to their original medical records and other participant-related trial
1784 documents for trial-related monitoring, audit, IRB/IEC review and regulatory
1785 inspection as part of the informed consent.

1786 3.17 **Reports**

1787 3.17.1 *Premature Termination or Suspension of a Trial*

1788 If a trial is prematurely terminated or suspended, the sponsor should promptly inform
1789 the investigators/institutions and the regulatory authority(ies) of the termination or
1790 suspension and the reason(s) for the termination or suspension. The IRB/IEC should
1791 also be informed promptly and provided with the reason(s) for the termination or
1792 suspension by the sponsor or by the investigator/institution, in accordance with
1793 applicable regulatory requirement(s).

1794 3.17.2 *Clinical Trial/Study Reports*

1795 (a) Whether the trial is completed or prematurely terminated or an interim analysis
1796 is undertaken for regulatory submission, the sponsor should ensure that the
1797 clinical trial reports, including interim reports, are prepared and provided to
1798 the regulatory agency(ies) as required by the applicable regulatory
1799 requirement(s). The sponsor should also ensure that the clinical trial reports in
1800 marketing applications meet the standards of ICH E3 or are otherwise in
1801 accordance with applicable regulatory requirements. (Note: ICH E3 specifies
1802 that abbreviated study reports may be acceptable in certain cases.)
1803

1804 (b) Investigators should be provided with a summary of the trial results.
1805

1806 (c) Consideration should be given to providing the investigator with information
1807 about the final treatment taken by their participants for blinded trials and a
1808 brief summary of the overall outcome of the trial. Where this information is
1809 provided to participants, the language should be non-technical, understandable
1810 to a layperson and non-promotional. The sponsor should only supply this
1811 information after the trial has been unblinded and all relevant
1812 analyses/conclusions have been completed and finalised.

4. DATA GOVERNANCE – INVESTIGATOR AND SPONSOR

This section provides guidance to investigators and sponsors (i.e., the responsible parties) on appropriate management of data integrity, traceability and security, thereby allowing the accurate reporting, verification and interpretation of the clinical trial-related information. This section should be read in conjunction with corresponding responsibilities for the investigator and the sponsor as defined in sections 2 and 3, along with ICH E8(R1) and ICH E9.

The quality and amount of the information generated in a clinical trial should be sufficient to address trial objectives, provide confidence in the trial's results and support good decision making.

The systems and processes that help ensure this quality should be designed and implemented in a way that is proportionate to the risks to participants and the reliability of trial results.

The following key processes should address the full data life cycle with a focus on the criticality of the data and should be implemented proportionately and documented appropriately:

- (a) processes to ensure data protection of trial participants' confidential data;
- (b) processes for managing computerised systems to ensure that they are fit for purpose and used appropriately;
- (c) processes to safeguard essential elements of the clinical trial, such as randomisation, dose escalation and blinding;
- (d) processes to support key decision making, such as data finalisation prior to analysis, unblinding, allocation to analysis data sets, changes in clinical trial design and, where applicable, the activities of, for example, an IDMC.

4.1 Safeguard Blinding in Data Governance

4.1.1 Maintaining the integrity of the blinding is important in particular in the design of systems, management of users' account, delegation of responsibilities with respect to data handling and provision of data access at sites, data transfers, database review prior to planned unblinding and statistical analysis across all appropriate stages of the trial.

4.1.2 Roles, responsibilities and procedures for access to unblinded information should be defined and documented by all relevant parties according to the protocol; this information may also be included in the data management plans and statistical analysis plans. For example, in blinded trials, sponsor staff or designated third parties who are involved in operation of the trial and directly or indirectly interact with site investigator staff should not have access to unblinding information.

4.1.3 The potential for unblinding should be part of the risk assessment of a blinded trial. Any planned or unplanned unblinding, including accidental or emergency unblinding, should be documented and assessed for impact to trial results.

4.2 Data Life Cycle Elements

Procedures should be in place to cover the full data life cycle.

4.2.1 Data Capture

(a) The requirements for and extent of data verification, when data captured on paper or in an electronic health record are manually transcribed into a computerised system, should take the criticality of the data into account. Refer to section 4.2.3 for data entered directly in data acquisition tools.

(b) Acquired data from any source should be accompanied by relevant metadata. At the point of data capture, automated data validation checks should be considered as required based upon risk, and their implementation should be controlled and documented.

4.2.2 Relevant Metadata, Including Audit Trails

The approach used by the responsible party for implementing, evaluating, accessing, managing and reviewing relevant metadata associated with critical data should entail:

(a) Evaluating the system for the types and content of metadata available to ensure that:

(i) computerised systems maintain logs of user account creation, changes to user roles and permissions and user access;

(ii) systems are designed to permit data changes in such a way that the initial data entry and any subsequent changes or deletions are documented, including, where appropriate, using a risk-based evaluation, the reason for the change if it is not implicit;

(iii) systems record and maintain workflow actions in addition to direct data entry/changes into the system.

(b) Ensuring that audit trails, reports and logs are not disabled or modified except in rare circumstances and only if a log of such action and justification is maintained;

(c) Ensuring that audit trails and logs are decipherable and can facilitate analysis;

(d) Ensuring that the automatic capture of date and time of data entries or transfer using data acquisition tools are unambiguous (e.g., coordinated universal time (UTC));

(e) Determining which of the identified metadata require review and retention.

1893 4.2.3 *Review of Data and Metadata*

1894 Procedures for review of trial-specific data, audit trails and other relevant metadata
 1895 should be in place. It should be a planned activity, and the extent and nature should
 1896 be adapted to the individual trial and adjusted based on experience during the trial.

1897 4.2.4 *Data Corrections*

1898 There should be processes to correct data errors that could impact the reliability of the
 1899 trial results. Corrections should be attributed to the entity making the correction,
 1900 justified and supported by source records around the time of original entry, and
 1901 performed in a timely manner.

1902 4.2.5 *Data Transfer, Exchange and Migration*

1903 Validated processes or other appropriate processes such as reconciliation should be in
 1904 place to ensure that electronic data transferred between computerised systems retains
 1905 its integrity and preserves its confidentiality. The transfer process should be
 1906 documented to ensure traceability, and data reconciliation should be implemented as
 1907 appropriate.

1908 4.2.6 *Finalisation of Data Sets Prior to Analysis*

1909 (a) Data of sufficient quality for interim and final analysis are achieved by
 1910 implementing timely and reliable processes for data capture, verification,
 1911 validation, review and rectification of errors and omissions that have a
 1912 meaningful impact on the safety of trial participants and/or the reliability of
 1913 the trial results.

1914
 1915 (b) Activities undertaken to finalise the data sets prior to analysis should be
 1916 confirmed and documented in accordance with pre-specified procedures.
 1917 These activities may include reconciliation of entered data and data sets or
 1918 reconciliation of relevant databases, correction of data errors and omissions,
 1919 medical coding, compilation and addressing the impact of non-compliance
 1920 including protocol deviations.

1921
 1922 (c) Data extraction and determination of data analysis sets should take place in
 1923 accordance with the planned statistical analysis and should be documented.

1924 4.3 **Computerised Systems**

1925 As described in sections 2 and 3, the responsibilities of the sponsor, investigator and
 1926 the activities of other parties with respect to a computerised system used in clinical
 1927 trials should be clear and documented. In summary, the sponsor is responsible for
 1928 ensuring that for computerised systems which they put in place, the expectations for
 1929 computerised systems as described in this section are addressed in a risk proportionate
 1930 manner. The sponsor should review whether the systems used by the
 1931 investigator/institution (e.g., electronic health records and other record keeping
 1932 systems for source data collection) are fit for purpose in the context of the trial. In the
 1933 event that the investigator/institution deploys systems specifically for the purposes of

1934		conducting clinical trials, the investigator/institution should ensure that the
1935		expectations are proportionately addressed and implemented.
1936		The responsible party should ensure that those developing computerised systems for
1937		clinical trials are aware of the intended purpose and the regulatory requirements that
1938		apply to them.
1939		It is recommended that representatives of intended participant populations and
1940		healthcare professionals are involved in the design of the system, where relevant, to
1941		ensure that computerised systems are suitable for use by the intended user population.
1942	4.3.1	<i>Procedures for the Use of Computerised Systems</i>
1943		Documented procedures should be in place to ensure the appropriate use of
1944		computerised systems in clinical trials for essential activities related to data collection,
1945		handling and management.
1946	4.3.2	<i>Training</i>
1947		The responsible party should ensure that those using computerised systems are
1948		appropriately trained in their use.
1949	4.4	Security of Computerised Systems
1950	4.4.1	The security of the trial data and records should be managed throughout the data life
1951		cycle.
1952		
1953	4.4.2	The responsible party should ensure that security controls are maintained for
1954		computerised systems. These controls should include user management and ongoing
1955		measures to prevent, detect and/or mitigate security breaches. Aspects such as user
1956		authentication requirements and password management, firewall settings, antivirus
1957		software, security patching, system monitoring and penetration testing should be
1958		considered.
1959		
1960	4.4.3	The responsible party should maintain adequate backup of the data.
1961		
1962	4.4.4	Procedures should cover the following: system security measures, data backup and
1963		disaster recovery.
1964	4.5	Validation of Computerised Systems
1965	4.5.1	The responsible party is responsible for the validation status of the system throughout
1966		its life cycle. The approach to validation of computerised systems should be based on
1967		a risk assessment that considers the intended use of the system; the purpose and
1968		importance of the data/record that is collected/generated, maintained and retained in
1969		the system; and the potential of the system to affect the well-being, rights and safety
1970		of trial participants and the reliability of trial results.
1971		
1972	4.5.2	Validation should demonstrate that the system conforms to the established
1973		requirements for completeness, accuracy, and reliability and is consistent with
1974		intended performance.

1975	4.5.3	Systems should be appropriately validated prior to use with adequate change control procedures implemented.
1976		
1977		
1978	4.5.4	Validation of changes should be based on risk and consider both previously collected and new data.
1979		
1980		
1981	4.5.5	Both basic system functionality and protocol specific configurations and customisations, including automated data entry checks and calculations, should be validated. Interfaces between systems should also be defined and validated. Different degrees of qualification/validation may be needed for bespoke systems, systems designed to be configured or systems where no alterations are needed.
1982		
1983		
1984		
1985		
1986		
1987	4.5.6	Where relevant, procedures should cover the following: system design, validation, and functionality testing; release; setup; installation and change control until decommissioning.
1988		
1989		
1990		
1991	4.5.7	The responsible party should ensure that the computerised systems used in clinical trial processes are qualified and validated, including those developed by other parties. They should ensure that qualification and validation documentation is maintained and retained.
1992		
1993		
1994		
1995		
1996	4.5.8	Validation should generally include defining the requirements and specifications for the system and their testing, along with the associated documentation, to ensure the system is fit for purpose, especially for critical functionality, such as randomisation, dosing and dose titrations and reductions, and collection of endpoint data.
1997		
1998		
1999		
2000		
2001	4.5.9	Unresolved issues, if any, should be justified and, where relevant, addressed by mitigations prior to and/or during the continued use of the system.
2002		
2003		
2004	4.5.10	The trial-specific systems (including updates resulting from protocol amendments) should only be implemented to enable the conduct of the trial by the investigator after all necessary approvals for the clinical trial have been received.
2005		
2006		
2007	4.6	System Failure
2008		Contingency procedures should be in place to prevent loss or lack of accessibility to data essential to participant safety, trial decisions or trial outcomes.
2009		
2010	4.7	Technical Support
2011	4.7.1	Where appropriate, there should be mechanisms (e.g., help desk support) in place to document, evaluate and manage issues with the computerised systems (e.g., raised by users), and there should be periodic review of these cumulative issues to identify those that are repeated and/or systemic.
2012		
2013		
2014		
2015		
2016	4.7.2	Defects and issues should be resolved according to their criticality. Issues with high criticality should be resolved in a timely manner.
2017		

2018 4.8 User Management

2019 4.8.1 Access controls are integral to computerised systems used in clinical trials to limit
2020 system access to authorised users and to ensure attributability to an individual. The
2021 security measures should be selected in such a way that they achieve the intended
2022 security and do not unduly impact user-friendliness.

2023 4.8.2 Procedures should be in place to ensure that user access rights are appropriately
2024 assigned based on a user's duties and functions, blinding arrangements and the
2025 organisation to which users belong. Access rights should be revoked when they are
2026 no longer needed.

2027 4.8.3 Authorised users and access privileges should be clearly documented, maintained and
2028 retained. These records should include any updates to a user's roles, access rights and
2029 permissions, and time of access privileges given (e.g., time stamp).

GLOSSARY

Adverse Events and Adverse Reaction-related definitions:

Adverse Event (AE): Any unfavourable medical occurrence in a trial participant. The adverse event does not necessarily have a causal relationship with the treatment.

Adverse Drug Reaction (ADR):

- in the pre-approval clinical experience with a new investigational product or its new usages (particularly as the therapeutic dose(s) may not be established): unfavourable and unintended responses, such as a sign (e.g., laboratory results), symptoms or disease related to any dose of a medicinal product where a causal relationship between a medicinal product and an adverse event is a reasonable possibility. The level of certainty about the relatedness of the adverse drug reaction to an investigational product will vary. If the ADR is suspected to be medicinal product-related with a high level of certainty, it should be included in the reference safety information (RSI) and/or the Investigator's Brochure (IB).
- for marketed medicinal products: a response to a drug that is noxious and unintended and that occurs at doses normally used in humans for prophylaxis, diagnosis or therapy of diseases or for modification of physiological function. (See ICH E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).

Serious Adverse Event (SAE): Any unfavourable medical occurrence that is considered serious at any dose if it:

- results in death
- is life-threatening
- requires inpatient hospitalisation or prolongation of existing hospitalisation
- results in persistent or significant disability/incapacity
- is a congenital anomaly/birth defect (see ICH E2A)

Suspected Unexpected Serious Adverse Reaction (SUSAR): an adverse reaction that meets three criteria: suspected, unexpected and serious.

- Suspected: There is a reasonable possibility that the drug caused the adverse drug reaction.
- Unexpected: An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., the RSI, see glossary term contained within the Investigator's Brochure or alternative documents according to applicable regulatory requirements. Refer to ICH E2F Development Safety Update Report for more information about RSI.
- Serious: See above for SAE.

2070 **Agreement**

2071 A document or set of documents describing the details of any arrangements on delegation or
 2072 transfer, distribution and/or sharing of activities and, if appropriate, on financial matters
 2073 between two or more parties. This could be in the form of a contract. The protocol may serve
 2074 as the basis of an agreement.

2075 **Applicable Regulatory Requirement(s)**

2076 Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational
 2077 products.

2078 **Assent**

2079 Affirmative agreement of a minor to participate in clinical trial. The absence of expression of
 2080 agreement or disagreement should not be interpreted as assent.

2081 **Audit**

2082 A systematic and independent examination of trial-related activities and records performed by
 2083 the sponsor, service provider (including contract research organisation (CRO)) or institution to
 2084 determine whether the evaluated trial-related activities were conducted and the data were
 2085 recorded, analysed and accurately reported according to the protocol, applicable standard
 2086 operating procedures (SOPs), Good Clinical Practice (GCP) and the applicable regulatory
 2087 requirement(s).

2088 **Audit Certificate**

2089 A declaration of confirmation by the auditor that an audit has taken place.

2090 **Audit Report**

2091 A record describing the conduct and outcome of the audit.

2092 **Audit Trail**

2093 Metadata records that allow reconstruction of the course of events by capturing details on
 2094 actions (manual or automated) performed relating to information and data collection and, where
 2095 applicable, to activities in computerised systems. The audit trail should show activities, initial
 2096 entry, and changes to data fields or records, by whom, when and, where applicable, why. In
 2097 computerised systems, the audit trail should be secure, computer generated and timestamped.

2098 **Blinding/Masking**

2099 A procedure in which one or more parties to the trial are kept unaware of the treatment
 2100 assignment(s). Single-blinding usually refers to the participant(s) being unaware, and double-
 2101 blinding usually refers to the participant(s), investigator(s) or other trial staff, as appropriate,
 2102 being unaware of the treatment assignment(s).

2103 **Case Report Form (CRF)**

2104 A tool designed to record protocol-required information to be reported by the investigator to
 2105 the sponsor on each trial participant (see **Data Acquisition Tool**).

2106

2107 **Certified Copy**

2108 A copy (irrespective of the type of media used) of the original record that has been verified
2109 (i.e., by a dated signature or by generation through a validated process) to have the same
2110 information as the original, including relevant metadata, where applicable.

2111 **Clinical Trial**

2112 Any interventional investigation in human participants intended to discover or verify the
2113 clinical, pharmacological and/or other pharmacodynamic effects of an investigational
2114 product(s); and/or to identify any adverse reactions to an investigational product(s); and/or to
2115 study absorption, distribution, metabolism and excretion of an investigational product(s) with
2116 the object of ascertaining its safety and/or efficacy.

2117 **Clinical Trial/Study Report (CSR)**

2118 A documented description of a trial of any investigational product conducted in human
2119 participants, in which the clinical and statistical description, presentations and analyses are
2120 fully integrated into a single report (see ICH E3 Structure and Content of Clinical Study
2121 Reports).

2122 **Comparator**

2123 An investigational or authorised medicinal product (i.e., active control), placebo or standard of
2124 care used as a reference in a clinical trial.

2125 **Compliance (in relation to trials)**

2126 Adherence to the trial-related requirements, GCP requirements and the applicable regulatory
2127 requirements.

2128 **Confidentiality**

2129 Prevention of disclosure to other than authorised individuals of a sponsor's proprietary
2130 information or of a participant's identity or their confidential information.

2131 **Coordinating Investigator**

2132 An investigator assigned the responsibility for the coordination of investigators at different
2133 investigator sites participating in a multicentre trial (if appropriate).

2134 **Computerised Systems Validation**

2135 A process of establishing and documenting that the specified requirements of a computerised
2136 system can be consistently fulfilled from design until decommissioning of the system or
2137 transition to a new system. The approach to validation should be based on a risk assessment
2138 that takes into consideration the intended use of the system and the potential of the system to
2139 affect trial participant protection and the reliability of trial results.

2140 **Contract Research Organisation (CRO)**

2141 See **Service Provider**.

2142

2143 **Data Acquisition Tool (DAT)**

2144 A paper or electronic tool designed to collect data and associated metadata from a data
2145 originator in a clinical trial according to the protocol and to report the data to the sponsor.

2146 The data originator may be a human (e.g., the participant or trial staff), a machine (e.g.,
2147 wearables and sensors) or an electronic transfer of data from one system to another (e.g.,
2148 extraction of data from an electronic health record or laboratory system).

2149 Examples of DATs include but are not limited to CRFs, interactive response technologies
2150 (IRTs), patient-reported outcomes (PROs), clinical outcome assessments (COAs) and wearable
2151 devices, irrespective of the media used.

2152 **Direct Access**

2153 Permission to examine, analyse and verify records that are important to the evaluation of a
2154 clinical trial and may be performed in person or remotely. Any party (e.g., domestic and foreign
2155 regulatory authorities, sponsor's monitors and auditors) with direct access should take
2156 reasonable precautions within the constraints of the applicable regulatory requirement(s) to
2157 maintain the confidentiality of participants' identities and their data and sponsor's proprietary
2158 information.

2159 **Essential Records**

2160 Essential records are the documents and data (and relevant metadata), in any format, associated
2161 with a clinical trial that facilitate the ongoing management of the trial and collectively allow
2162 the evaluation of the methods used, the factors affecting a trial and the actions taken during the
2163 trial conduct to determine the reliability of the trial results produced and the verification that
2164 the trial was conducted in accordance with GCP and applicable regulatory requirements (see
2165 Appendix C. Essential Records for the Conduct of a Clinical Trial).

2166 **Good Clinical Practice (GCP)**

2167 A standard for the planning, initiating, performing, recording, oversight, evaluation, analysis
2168 and reporting of clinical trials that provides assurance that the data and reported results are
2169 reliable and that the rights, safety and well-being of trial participants are protected.

2170 **Impartial Witness**

2171 A person who is independent of the trial who cannot be unfairly influenced by people involved
2172 with the trial, who attends the informed consent process if the participant or the participant's
2173 legally acceptable representative cannot read, and who reads the informed consent form and
2174 any other documented information supplied or read to the participant and/or their legally
2175 acceptable representative.

2176 **Independent Data Monitoring Committee (IDMC)**

2177 An independent data monitoring committee (e.g., data safety monitoring board) that may be
2178 established by the sponsor to assess at intervals the progress of a clinical trial, the safety data
2179 and the critical efficacy endpoints, and to recommend to the sponsor whether to continue,
2180 modify or stop a trial.

2181

2182 **Informed Consent**

2183 A process by which a participant or their legally accepted representative voluntarily confirms
 2184 their willingness to participate in a trial after having been informed and been provided with the
 2185 opportunity to discuss all aspects of the trial that are relevant to the participant's decision to
 2186 participate. Varied approaches to the provision of information and the discussion about the trial
 2187 can be used. This can include, for example, providing text in different formats, images and
 2188 videos and using telephone or video conferencing with investigator site staff. Informed consent
 2189 is documented by means of a written or electronic, signed and dated informed consent form.
 2190 Obtaining consent remotely may be considered when appropriate.

2191 **Inspection**

2192 The act by a regulatory authority(ies) of conducting an official review of documents, facilities,
 2193 records and any other resources that are deemed by the authority(ies) to be related to the clinical
 2194 trial and that may be accessed at the investigator site, at the sponsor's and/or service provider's
 2195 (including CRO's) facilities, or at other establishments deemed appropriate by the regulatory
 2196 authority(ies). Some aspects of the inspection may be conducted remotely.

2197 **Institution**

2198 Any public or private entity or agency or medical or dental organisation in whose remit clinical
 2199 trials are conducted.

2200 **Institutional Review Board (IRB)/Independent Ethics Committee (IEC)**

2201 An independent body (a review board or a committee, institutional, regional, national or
 2202 supranational) constituted of medical professionals and non-medical members whose
 2203 responsibility it is to ensure the protection of the rights, safety and well-being of human
 2204 participants involved in a trial and to provide public assurance of that protection by, among
 2205 other things, reviewing and approving/providing favourable opinion on the trial protocol, the
 2206 suitability of the investigator(s), the facilities, and the methods and material to be used in
 2207 obtaining and documenting informed consent of the trial participants. The legal status,
 2208 composition, function, operations and regulatory requirements pertaining to IRBs/IECs may
 2209 differ among countries but should allow the IRB/IEC to act in agreement with GCP as
 2210 described in this guideline.

2211 **Interim Clinical Trial/Study Report**

2212 A report of intermediate results and their evaluation based on analyses performed during the
 2213 course of a trial.

2214 **Investigational Product**

2215 A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in
 2216 a clinical trial, including a product with a marketing authorisation when used or assembled
 2217 (formulated or packaged) in a way different from the approved form, or when used for an
 2218 unapproved indication, or when used to gain further information about an approved use.

2219

2220

2221 **Investigator**

2222 A person responsible for the conduct of the clinical trial, including the trial participants for
2223 whom that person has responsibility during the conduct of the trial. If a trial is conducted by a
2224 team of individuals, the investigator is the responsible leader of the team and may be called the
2225 principal investigator. Where an investigator/institution is referenced in this guideline, it
2226 describes expectations that may be applicable to the investigator and/or the institution in some
2227 regions. Where required by the applicable regulatory requirements, the “investigator” should
2228 be read as “investigator and/or the institution.”

2229 **Investigator’s Brochure (IB)**

2230 A compilation of the clinical and nonclinical data on the investigational product(s) that is
2231 relevant to the study of the investigational product(s) in human participants (see Appendix A.
2232 Investigator’s Brochure).

2233 **Investigator Site**

2234 The location(s) at or from where trial-related activities are conducted under the
2235 investigator’s/institution’s supervision.

2236 **Legally Acceptable Representative**

2237 An individual or juridical or other body authorised under applicable law to consent, on behalf
2238 of a prospective participant, to the participant’s participation in the clinical trial.

2239 **Metadata**

2240 The contextual information required to understand a given data element. Metadata is structured
2241 information that describes, explains or otherwise makes it easier to retrieve, use or manage
2242 data. For the purpose of this guideline, relevant metadata are those needed to reconstruct the
2243 trial conduct.

2244 **Monitoring**

2245 The act of overseeing the progress of a clinical trial and of ensuring that the clinical trial is
2246 conducted, recorded and reported in accordance with the protocol, SOPs, GCP and the
2247 applicable regulatory requirement(s).

2248 **Monitoring Plan**

2249 A document that describes the strategy, methods, responsibilities and requirements for
2250 monitoring the trial.

2251 **Monitoring Report**

2252 A documented report following site and/or centralised monitoring activities.

2253 **Multicentre Trial**

2254 A clinical trial conducted according to a single protocol but at more than one investigator site.

2255 **Nonclinical Study**

2256 Biomedical studies not performed on human participants.

2257 **Original Medical Record**

2258 See **Source Records**.

2259 **Protocol**

2260 A document that describes the objective(s), design, methodology, statistical considerations and
2261 organisation of a trial. The protocol usually also gives the background and rationale for the
2262 trial, but these could be provided in other protocol referenced documents. Throughout the ICH
2263 GCP Guideline, the term protocol refers to protocol and protocol amendments.

2264 **Protocol Amendment**

2265 A documented description of a change(s) to a protocol.

2266 **Quality Assurance (QA)**

2267 All those planned and systematic actions that are established to ensure that the trial is performed
2268 and the data are generated, documented (recorded) and reported in compliance with GCP and
2269 the applicable regulatory requirement(s).

2270 **Quality Control (QC)**

2271 The operational techniques and activities undertaken to verify that the requirements for quality
2272 of the trial-related activities have been fulfilled.

2273 **Randomisation**

2274 The process of deliberately including an element of chance when assigning participants to
2275 groups that receive different treatments in order to reduce bias.

2276 **Reference Safety Information (RSI)**

2277 Contains a cumulative list of ADRs that are expected for the investigational product being
2278 administered to participants in a clinical trial. The RSI is included in the Investigator's
2279 Brochure.

2280 **Regulatory Authorities**

2281 Bodies having the power to regulate, including those that review submitted protocols and
2282 clinical data and those that conduct inspections. These bodies are sometimes referred to as
2283 competent authorities.

2284 **Service Provider**

2285 A person or organisation (commercial, academic or other) providing a service used during the
2286 conduct of a clinical trial to either the sponsor or the investigator to fulfil one or more of their
2287 trial-related activities.

2288 **Signature**

2289 A unique mark, symbol or entry in line with applicable regulatory requirements and/or practice
2290 to show expression of will and allow authentication of the signatory.

2291

2292 **Source Records**

2293 Original documents or data (which includes relevant metadata) or certified copies of the
 2294 original documents or data, irrespective of the media used. This may include trial participants’
 2295 medical/health records/notes/charts; data provided/entered by trial participants (e.g., electronic
 2296 patient-reported outcome (ePROs)); healthcare providers’ records from pharmacies,
 2297 laboratories and other facilities involved in the clinical trial; and data from automated
 2298 instruments, such as wearables and sensors.

2299 **Sponsor**

2300 An individual, company, institution, or organisation that takes responsibility for the initiation,
 2301 management and arrangement of the financing of a clinical trial. A clinical trial may have one
 2302 or several sponsors where permitted under regulatory requirements. All sponsors have the
 2303 responsibilities of a sponsor set out in this guideline. In accordance with regulatory
 2304 requirements, sponsors may decide in a documented agreement setting out their respective
 2305 responsibilities. Where the agreement does not specify to which sponsor a given responsibility
 2306 is attributed, that responsibility lies with all sponsors.

2307 **Sponsor-Investigator**

2308 An individual who both initiates and conducts, alone or with others, a clinical trial, and under
 2309 whose immediate direction the investigational product is administered to, dispensed to or used
 2310 by a participant. The term does not include any person other than an individual (e.g., the term
 2311 does not include a corporation or an agency). The obligations of a sponsor-investigator include
 2312 both those of a sponsor and those of an investigator.

2313 **Standard Operating Procedures (SOPs)**

2314 Detailed, documented instructions to achieve uniformity of the performance of a specific
 2315 activity.

2316 **Sub-investigator**

2317 Any individual member of the clinical trial team designated and supervised by the investigator
 2318 to perform critical trial-related procedures and/or to make important trial-related decisions
 2319 (e.g., associates, residents, research fellows).

2320 **Trial Participant**

2321 An individual who participates in a clinical trial, either as a recipient of the investigational
 2322 product(s) or as a control.

2323 **Trial Participant Identification Code**

2324 A unique identifier assigned to each trial participant to protect the participant’s identity and
 2325 used in lieu of the participant’s name when the investigator reports adverse events and/or other
 2326 trial-related data.

2327 **Vulnerable Participants**

2328 Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the
 2329 expectation, whether justified or not, of benefits associated with participation or of a retaliatory

2330 response from senior members of a hierarchy in case of refusal to participate. Examples are
2331 members of a group with a hierarchical structure, such as medical, pharmacy, dental and
2332 nursing students; subordinate hospital and laboratory personnel; employees of the
2333 pharmaceutical industry; members of the armed forces and persons kept in detention. Other
2334 vulnerable participants may include persons in nursing homes, unemployed or impoverished
2335 persons, patients in emergency situations, ethnic minority groups, homeless persons, nomads,
2336 refugees, minors and those incapable of giving consent.

APPENDICES

Appendix A. INVESTIGATOR'S BROCHURE

A.1 Introduction

The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s)¹ that are relevant to the study of the product(s) in human participants. Its purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for and their compliance with many key features of the protocol, such as the dose, dose frequency/interval, methods of administration and safety monitoring procedures.

A.1.1 *Development of the Investigator's Brochure*

Generally, the sponsor is responsible for ensuring that an up-to-date IB is developed. In the case of an investigator-initiated trial, the sponsor-investigator should determine whether a brochure is available from the product license/marketing authorisation holder. If the investigational product is provided by the sponsor-investigator, then they should provide the necessary information to the investigator site staff. Where permitted by regulatory authorities, the current scientific information such as a basic product information brochure (e.g., summary of product characteristics package leaflet, or labelling) may be an appropriate alternative, provided that it includes current, comprehensive and detailed information on all aspects of the investigational product that might be of importance to the investigator. If an authorised medicinal product is being studied for a new use (i.e., a new indication), an IB specific to that new use should be prepared unless there is a rationale for only one IB. The IB should be reviewed at least annually and revised as necessary in compliance with a sponsor's documented procedures. More frequent revision may be appropriate depending on the stage of development and the generation of relevant new information. Relevant new information may be so important that it needs to be communicated to the investigators and possibly to the IRBs/IECs and/or regulatory authorities before it is included in a revised IB.

A.1.2 *Reference Safety Information and Risk-Benefit Assessment*

The reference safety information (RSI) contained in the IB provides an important reference point for expedited reporting of suspected unexpected serious adverse reactions (SUSARs) in the clinical trial. The IB also provides insight to support the clinical management of the participants during the course of the clinical trial. The information should be presented in a concise, simple, objective, balanced and non-promotional form that enables a clinician or potential investigator to understand it and make their own unbiased risk-benefit assessment of the appropriateness of the proposed trial. For this reason, a medically qualified person should be involved in the generation of an IB, but the contents of the IB should be approved by the disciplines that generated the described data.

¹ For the purpose of this guideline, the term "investigational products" should be considered synonymous with drugs, medicines, medicinal products, vaccines and biological products.

2378 **A.2 General Considerations**

2379 These considerations delineate the minimum information that should be included in an IB. It is
 2380 expected that the type and extent of information available will vary with the stage of
 2381 development of the investigational product.

2382 The IB should include;

2383 *A.2.1 Title Page*

2384 This should provide the sponsor's name, the identity of each investigational product
 2385 (i.e., research number, chemical or approved generic name and trade name(s) where
 2386 legally permissible and desired by the sponsor) and the release date. It is also
 2387 suggested that an edition number and a reference to the number and date of the edition
 2388 it supersedes be provided along with the cut-off date for data inclusion in the version.
 2389 Where appropriate, a signature page may be included.

2390 *A.2.2 Confidentiality Statement*

2391 The sponsor may wish to include a statement instructing the investigator and other
 2392 recipients to treat the IB as a confidential document for the sole information and use
 2393 of the investigator/institution, investigator site staff, regulatory authorities and the
 2394 institutional review board/independent ethics committee (IRB/IEC).

2395 **A.3 Contents of the Investigator's Brochure**

2396 The IB should contain the following sections, each with literature references (publications or
 2397 reports) included at the end of each chapter, where appropriate;

2398 *A.3.1 Table of Contents*

2399 *A.3.2 Summary*

2400 A brief summary (preferably not exceeding two pages) should be given, highlighting
 2401 the significant physical, chemical, pharmaceutical, pharmacological, toxicological,
 2402 pharmacokinetic, metabolic and clinical information available that is relevant to the
 2403 stage of clinical development of the investigational product.

2404 *A.3.3 Introduction*

2405 A brief introductory statement should be provided that contains the chemical name
 2406 (and generic and trade name(s) when approved) of the investigational product(s); all
 2407 active ingredients; the pharmacological class of the investigational product(s) and its
 2408 expected position within this class (e.g., advantages); the rationale for performing
 2409 research with the investigational product(s); and the anticipated prophylactic,
 2410 therapeutic or diagnostic indication(s). Finally, the introductory statement should
 2411 provide the general approach to be followed in evaluating the investigational product.

2412 *A.3.4 Physical, Chemical and Pharmaceutical Properties and Formulation*

2413 A description should be provided of the investigational product substance(s)
 2414 (including the chemical and/or structural formula(e)), and a brief summary should be
 2415 given of the relevant physical, chemical and pharmaceutical properties.

2416 To permit appropriate safety measures to be taken in the course of the trial, a
 2417 description of the formulation(s) to be used, including excipients, should be provided
 2418 and justified if clinically relevant. Instructions for the storage and handling of the
 2419 dosage form(s) should also be given.

2420 Any structural similarities to other known compounds should be mentioned.

2421 A.3.5 *Nonclinical Studies*

2422 *Introduction*

2423 The results of all relevant nonclinical pharmacology, toxicology, pharmacokinetic and
 2424 investigational product metabolism studies should be provided in summary form. This
 2425 summary should address the methodology used, the results and a discussion of the
 2426 relevance of the findings to the investigated therapeutic and the possible unfavourable
 2427 and unintended effects in humans.

2428 The information provided may include the following, as appropriate, if
 2429 known/available:

- 2430 • species tested
- 2431 • number and sex of animals in each group
- 2432 • unit dose (e.g., milligram/kilogram (mg/kg))
- 2433 • dose interval
- 2434 • route of administration
- 2435 • duration of dosing
- 2436 • information on systemic distribution
- 2437 • duration of post-exposure follow-up
- 2438 • results, including the following aspects:
 - 2439 – nature and frequency of pharmacological or toxic effects
 - 2440 – severity or intensity of pharmacological or toxic effects
 - 2441 – time to onset of effects
 - 2442 – reversibility of effects
 - 2443 – duration of effects
 - 2444 – dose response

2445 Tabular format/listings should be used whenever possible to enhance the clarity of the
 2446 presentation.

2447 The following sections should discuss the most important findings from the studies,
 2448 including the dose response of observed effects, the relevance to humans and any
 2449 aspects to be studied in humans. If applicable, the effective and nontoxic dose findings
 2450 in the same animal species should be compared (i.e., the therapeutic index should be
 2451 discussed). The relevance of this information to the proposed human dosing should
 2452 be addressed. Whenever possible, comparisons should be made in terms of
 2453 blood/tissue levels rather than on a mg/kg basis.

2454 (a) *Nonclinical Pharmacology*

2455 A summary of the pharmacological aspects of the investigational product and, where
 2456 appropriate, its significant metabolites studied in animals should be included. Such a

2457 summary should incorporate studies that assess potential therapeutic activity (e.g.,
 2458 efficacy models, receptor binding and specificity) as well as those that assess safety
 2459 (e.g., special studies to assess pharmacological actions other than the intended
 2460 therapeutic effect(s)).

2461 *(b) Pharmacokinetics and Product Metabolism in Animals*

2462 A summary of the pharmacokinetics and biological transformation and disposition of
 2463 the investigational product in all species studied should be given. The discussion of
 2464 the findings should address the absorption and the local and systemic bioavailability
 2465 of the investigational product and its metabolites and their relationship to the
 2466 pharmacological and toxicological findings in animal species.

2467 *(c) Toxicology*

2468 A summary of the toxicological effects found in relevant studies conducted in
 2469 different animal species should be described under the following headings where
 2470 appropriate:

- 2471 • single dose
- 2472 • repeated dose
- 2473 • carcinogenicity
- 2474 • special studies (e.g., irritancy and sensitisation)
- 2475 • reproductive toxicity
- 2476 • genotoxicity (mutagenicity)

2477 *A.3.6 Effects in Humans*

2478 *Introduction*

2479 A thorough discussion of the known effects of the investigational product(s) in
 2480 humans should be provided, including information on pharmacokinetics, metabolism,
 2481 pharmacodynamics, dose response, safety, efficacy and other pharmacological
 2482 activities. Where possible, a summary of each completed clinical trial and ongoing
 2483 trials where interim results are available that may inform the safety evaluation should
 2484 be provided. Information should also be provided regarding results of any use of the
 2485 investigational product(s) other than from in clinical trials, such as from experience
 2486 during marketing.

2487 *(a) Pharmacokinetics and Product Metabolism in Humans*

2488 A summary of information on the pharmacokinetics of the investigational product(s)
 2489 should be presented, including the following, if available:

- 2490 • pharmacokinetics (including metabolism, as appropriate, and absorption,
 2491 plasma protein binding, distribution and elimination)
- 2492 • bioavailability of the investigational product (absolute, where possible, and/or
 2493 relative) using a reference dosage form
- 2494 • population subgroups (e.g., sex, age and impaired organ function)
- 2495 • interactions (e.g., product-product interactions and effects of food)

- other pharmacokinetic data (e.g., results of population studies performed within clinical trial(s))

(b) Safety and Efficacy

A summary of information should be provided about the investigational product's/products' (including metabolites, where appropriate) safety, pharmacodynamics, efficacy and dose response that was obtained from preceding trials in humans (healthy volunteers and/or patients). The implications of this information should be discussed. In cases where a number of clinical trials have been completed, the use of summaries of safety and efficacy across multiple trials by indications in subgroups may provide a clear presentation of the data. Tabular summaries of adverse drug reactions for all the clinical trials (including those for all the studied indications) would be useful. Important differences in adverse drug reaction patterns/incidences across indications or subgroups should be discussed.

The IB should provide a description of the possible risks and adverse drug reactions to be anticipated on the basis of prior experiences with the product under investigation and with related products. There should be a list of adverse reactions, clearly identified as the reference safety information section, including information on their frequency and nature. This list should be used for determining the expectedness of a suspected serious adverse reaction and subsequently whether it needs to be expedited in accordance with regulatory requirements. A description should also be provided of the precautions or special monitoring to be done as part of the investigational use of the product(s).

(c) Marketing Experience

The IB should identify countries where the investigational product has been marketed or approved. Any significant information arising from the marketed use should be summarised (e.g., formulations, dosages, routes of administration, adverse drug reactions). The IB should also identify all the countries where the investigational product did not receive approval/registration for marketing or was withdrawn from marketing/registration.

A.3.7 Summary of Data and Guidance for the Investigator

This section should provide an overall discussion of the nonclinical and clinical data and should summarise the information from various sources on different aspects of the investigational product(s), wherever possible. In this way, the investigator can be provided with the most informative interpretation of the available data and with an assessment of the implications of the information for future clinical trials.

Where appropriate, the published reports on related products should be discussed. This could help the investigator to anticipate adverse drug reactions or other problems in clinical trials.

The overall aim of this section is to provide the investigator with a clear understanding of the possible risks and adverse reactions and of the specific tests, observations and precautions that may be needed for a clinical trial. This understanding should be based on the available physical,

2538 chemical, pharmaceutical, pharmacological, toxicological and clinical information on the
2539 investigational product(s). Guidance should also be provided to the clinical investigator on the
2540 recognition and treatment of possible overdose and adverse drug reactions that is based on
2541 previous human experience and on the pharmacology of the investigational product.

2542 **Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)**

2543 Clinical trials should be described in a clear, concise and operationally feasible protocol. The
 2544 protocol should be designed in such a way as to minimise unnecessary complexity and to
 2545 mitigate or eliminate important risks to the rights, safety, and wellbeing of trial participants
 2546 and the reliability of data. Protocol development processes should incorporate input from
 2547 relevant stakeholders, where appropriate. Building adaptability into the protocol, for example,
 2548 by including acceptable ranges for specific protocol provisions, can reduce the number of
 2549 deviations or in some instances the requirement for a protocol amendment. Such adaptability
 2550 should not adversely affect participant safety or the scientific validity of the trial. For additional
 2551 information, refer to ICH E8(R1) General Considerations for Clinical Studies and ICH E9
 2552 Statistical Principles for Clinical Trials.

2553 The contents of a trial protocol should generally include the following topics, which may vary
 2554 depending on the trial design. Investigator site-specific information may be provided on
 2555 separate protocol page(s) or addressed in a separate agreement, and some of the information
 2556 listed below may be contained in other protocol referenced documents, such as an
 2557 Investigator's Brochure.

2558 **B.1 General Information**

2559 B.1.1 Protocol title, unique protocol identifying number, and date. Any amendment(s)
 2560 should also bear the amendment number(s) and date(s).

2561 B.1.2 Name and address of the sponsor.

2562 B.1.3 Name and title of the person(s) authorised to sign the protocol and the protocol
 2563 amendment(s) for the sponsor.

2564 **B.2 Background Information**

2565 B.2.1 Name and description of the investigational product(s).

2566 B.2.2 A summary of findings from nonclinical studies that potentially have clinical
 2567 significance and from clinical trials that are relevant to the trial.

2568 B.2.3 Summary of the known and potential risks and benefits, if any, to human participants.

2569 B.2.4 Description of and justification for the route of administration, dosage, dosage
 2570 regimen and treatment period(s).

2571 B.2.5 A statement that the trial will be conducted in compliance with the protocol, Good
 2572 Clinical Practice (GCP) and the applicable regulatory requirement(s).

2573 B.2.6 Description of the population to be studied.

2574 B.2.7 References to literature and data that are relevant to the trial and that provide
 2575 background for the trial.

2576 **B.3 Trial Objectives and Purpose**

2577 A clear description of the scientific objectives and the purpose of the trial. Information on
 2578 estimands, where appropriate, if not included in any other trial-related document, see ICH

2579 E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline
2580 on Statistical Principles for Clinical Trials.

2581 **B.4 Trial Design**

2582 The scientific integrity of the trial and the reliability of the results from the trial depend
2583 substantially on the trial design. A description of the trial design should include:

2584 B.4.1 A specific statement of the primary endpoints and the secondary endpoints, if any, to
2585 be measured during the trial.

2586 B.4.2 A description of the type and design of trial to be conducted (e.g., double-blind,
2587 placebo-controlled, parallel design, adaptive design, platform/umbrella/basket, trials
2588 with decentralised elements) and a schematic diagram of trial design, procedures and
2589 stages.

2590 B.4.3 A description of the measures taken to minimise/avoid bias, including:

2591 (a) Randomisation

2592 (b) Blinding

2593 B.4.4 A description of the trial treatment(s) and the dosage and dosage regimen of the
2594 investigational product(s), including a description of the dosage form, packaging and
2595 labelling.

2596 B.4.5 The expected duration of the participant's involvement in the trial and a description
2597 of the sequence and duration of all trial periods, including follow-up, if any.

2598 B.4.6 A description of the “stopping rules” or “discontinuation criteria” and “dose
2599 adjustment” or “dose interruption” for individual participants, parts of trial and entire
2600 trial.

2601 B.4.7 Accountability procedures for the investigational product(s), including the placebo(s)
2602 and other comparator(s), if any.

2603 B.4.8 Maintenance of treatment randomisation codes and procedures for breaking codes.

2604 **B.5 Selection of Participants**

2605 B.5.1 Participant inclusion criteria.

2606 B.5.2 Participant exclusion criteria.

2607 B.5.3 Mechanism for pre-screening, where appropriate, and screening of participants.

2608 **B.6 Withdrawal of Consent or Discontinuation of Participation**

2609 The investigator may choose to discontinue the participant, or the participant may
2610 withdraw their consent. The protocol should specify:

2611 (a) when and how to discontinue participants from the trial/investigational product
2612 treatment;

- 2613 (b) the type and timing of the data to be collected for withdrawn/discontinued
2614 participants, including the process by which the data are handled, in accordance
2615 with applicable regulatory requirements;
- 2616 (c) whether and how participants are to be replaced;
- 2617 (d) the follow-up for participants who have discontinued the use of the
2618 investigational product.

2619 **B.7 Treatment and Interventions for Participants**

2620 B.7.1 The treatment(s) to be administered, including the name(s) of all the product(s), the
2621 dose(s), the dosing schedule(s), the criteria for dose adjustment(s), the route/mode(s)
2622 of administration and the treatment period(s), including the follow-up period(s) for
2623 participants for each investigational product treatment/trial treatment group/arm of the
2624 trial.

2625 B.7.2 Medication(s)/treatment(s) permitted (including concomitant and rescue medication)
2626 and not permitted before and/or during the trial.

2627 B.7.3 Strategies to monitor the participant's adherence to treatment.

2628 **B.8 Assessment of Efficacy**

2629 B.8.1 Specification of the efficacy parameters, where applicable.

2630 B.8.2 Methods and timing for assessing, recording and analysing of efficacy parameters.
2631 Where any trial-related committees (e.g., independent data monitoring committee
2632 (IDMC)/adjudication committees) are utilised for the purpose of assessing efficacy
2633 data, procedures, timing and activities should be described in the protocol or a separate
2634 document.

2635 **B.9 Assessment of Safety**

2636 B.9.1 Specification of safety parameters.

2637 B.9.2 The methods, extent and timing for recording and assessing safety parameters. Where
2638 any trial-related committees (e.g., IDMC) are utilised for the purpose of assessing
2639 safety data, procedures, timing and activities should be described in the protocol or a
2640 separate document.

2641 B.9.3 Procedures for obtaining reports of and for recording and reporting adverse event and
2642 intercurrent events; see ICH E9(R1).

2643 B.9.4 The type and duration of the follow-up of participants after adverse events.

2644 **B.10 Statistical Considerations**

2645 B.10.1 A description of the statistical methods to be employed, including timing and purpose
2646 of any planned interim analysis(es) and the criteria for the stopping of the trial.

2647 B.10.2 The number of participants planned to be enrolled and the reason for the choice of
2648 sample size, including reflections on or calculations of the power of the trial and
2649 clinical justification.

- 2650 B.10.3 The level of significance to be used or the threshold for success on the posterior
2651 probability in a Bayesian design.
- 2652 B.10.4 The criteria for the termination of the trial and the criteria for the stopping of the trial.
- 2653 B.10.5 The selection of participants to be included in the planned analyses (e.g., all
2654 randomised participants, all dosed participants, all eligible participants, all evaluable
2655 participants).
- 2656 B.10.6 Procedures for accounting for missing, unused and spurious data.
- 2657 B.10.7 Statement that any deviation(s) from the statistical analysis plan will be described and
2658 justified in the clinical study report.
- 2659 **B.11 Direct Access to Source Records**
- 2660 The sponsor should ensure that it is specified in the protocol or other documented agreement
2661 that the investigator(s)/institution(s)/service provider(s) will permit trial-related monitoring,
2662 audits, institutional review board/independent ethics committee (IRB/IEC) review and
2663 regulatory inspection(s), providing direct access to source records.
- 2664 **B.12 Quality Control and Quality Assurance**
- 2665 B.12.1 Description of identified quality factors and associated risks in the trial unless
2666 documented elsewhere.
- 2667 B.12.2 Description of the monitoring approaches that are part of the quality control process
2668 for the clinical trial.
- 2669 B.12.3 Description of the process for the handling of non-compliance with the protocol or
2670 GCP.
- 2671 **B.13 Ethics**
- 2672 Description of ethical considerations relating to the trial.
- 2673 **B.14 Data Handling and Record Keeping**
- 2674 B.14.1 Specification of data to be collected and the method of its collection. Where necessary,
2675 additional details should be contained in a clinical trial-related document.
- 2676 B.14.2 The identification of records to be recorded directly into the data acquisition tools
2677 (i.e., no prior written or electronic record of data) and considered to be source data.
- 2678 B.14.3 A statement that records should be retained in accordance with applicable regulatory
2679 requirements.
- 2680 **B.15 Financing and Insurance**
- 2681 Financing and insurance, if not addressed in a separate agreement.
- 2682 **B.16 Publication Policy**
- 2683 Publication policy, if not addressed in a separate agreement.

Appendix C. ESSENTIAL RECORDS FOR THE CONDUCT OF A CLINICAL TRIAL**C.1 Introduction**

C.1.1 Many records are generated before and during the conduct of a clinical trial. The nature and extent of those records generated and maintained are dependent upon the trial design, its conduct, application of proportional approaches and the importance and relevance of that record to the trial.

C.1.2 Determining which records are essential will be based upon consideration of the guidance in this appendix.

C.1.3 The essential records permit and contribute to the evaluation of the conduct of a trial and the reliability of the results produced. They serve to demonstrate the compliance of the investigator and sponsor with the standards of Good Clinical Practice (GCP) and applicable regulatory requirements. The essential records are used as part of the sponsor oversight or investigator supervision of the trial. These records are used by the sponsor's independent audit function and during inspections by regulatory authority(ies) to assess the trial conduct and the reliability of the trial results. The investigator/institution should have access to and the ability to maintain and retain the essential records generated by the investigator/institution before, during and after the trial.

C.2 Management of Essential Records

C.2.1 Records should be identifiable and version controlled, and should include authors, reviewers and approvers as appropriate, along with date and signature (electronic or wet ink), where necessary.

C.2.2 For activities that are transferred or delegated to service providers by the sponsor or investigator/institution respectively, arrangements should be made for the access and management of the essential records throughout the trial and for their retention following completion of the trial.

C.2.3 These essential records should be maintained in or referred to from repositories, including, for example, the trial master file (TMF) or investigator site file (ISF). The TMF is held by the sponsor or by the investigator; in the latter case, it is often called the ISF.

C.2.4 The sponsor and investigator/institution should maintain a record of where essential records are located, including source records. The storage system(s) used during the trial and for archiving (irrespective of the type of media used) should provide for appropriate identification, version history, search and retrieval of trial records.

C.2.5 The sponsor and investigator/institution should ensure that the essential records are collected and filed in a timely manner, including those required to be in place prior to the trial start, which can greatly assist in the successful management of a trial.

- 2727 C.2.6 The sponsor and investigator/institution should retain the essential records in a way
2728 that ensures that they remain complete, readable and readily available and are directly
2729 accessible upon request by regulatory authorities. Alteration to the essential records
2730 should be traceable.
2731
- 2732 C.2.7 The original version of the essential record should be retained by the responsible party
2733 (sponsor or investigator). When a copy is used to permanently replace the original
2734 essential record, the copy should fulfil the requirements for certified copies.
2735
- 2736 C.2.8 In order to fulfil their responsibilities in the conduct of the trial, the sponsor and
2737 investigator/institution may need access to or copies of one another's relevant
2738 essential records before, during and after the trial is completed. This will determine
2739 whether the record resides in the repositories of the sponsor, the
2740 investigator/institution, or both. There should be careful consideration of sharing of
2741 records subject to data protection legislation and blinding considerations in line with
2742 applicable regulatory requirements. For the sharing of essential records with service
2743 providers, see section C.2.2.
2744
- 2745 C.2.9 Certain essential records may not be specific to a trial but may be related to the
2746 systems and processes involved in running multiple trials and retained outside the
2747 trial-specific repositories (e.g., standard operating procedures validation records,
2748 master services agreements).
- 2749 **C.3 Essentiality of Trial Records**
- 2750 C.3.1 Whether a specific clinical trial record generated before, during and after the trial is
2751 essential and needs to be retained should be based on the following criteria:
- 2752 (a) Is a document that is submitted to or issued by the regulatory authority or
2753 IRB/IEC, including related correspondence and those documenting regulatory
2754 decisions or approvals/favourable opinions;
 - 2755 (b) Is a trial-specific procedure or plan;
 - 2756 (c) Is relevant correspondence or documentation of meetings related to important
2757 discussions and/or trial-related decisions that have been made related to the
2758 conduct of the trial and the processes being used;
 - 2759 (d) Documents the conduct of relevant trial procedures;
 - 2760 (e) Documents the arrangements between parties and insurance/indemnity
2761 arrangements;
 - 2762 (f) Documents the compliance with the requirements and any conditions of
2763 approval from the regulatory authority or the favourable opinion of the
2764 institutional review board/independent ethics committee (IRB/IEC);
 - 2765 (g) Documents the composition and, where appropriate, the functions,
2766 correspondence and decisions of any committees involved in the trial approval
2767 or its conduct.

- 2768 (h) Demonstrates that a trial-specific computerised system is validated and that
2769 non-trial-specific systems have been assessed as fit for purpose for their
2770 intended use in the trial;
- 2771 (i) Is a document that has been authorised/signed by the sponsor and/or
2772 investigator to confirm review or approval;
- 2773 (j) Is, where necessary, documentation that demonstrates signatures/initials of staff
2774 undertaking trial-specific activities; for example, completing data acquisition
2775 tools;
- 2776 (k) Documents what information was provided to potential trial participants and
2777 that participants' informed consent was appropriately obtained and maintained;
- 2778 (l) Documents that sponsor personnel involved in the trial conduct and individuals
2779 performing trial-specific activities on their behalf are qualified by education,
2780 training and experience to undertake their activities;
- 2781 (m) Documents that the investigator and those individuals delegated trial-specific
2782 activities by the investigator are qualified by education, training and experience
2783 to undertake their activities, particularly where the activities are not part of their
2784 normal role;
- 2785 (n) Contains the data as well as relevant metadata that would be needed to be able
2786 to reconstruct the trial;
- 2787 (o) Are documents related to the sponsor and investigator oversight of safety of
2788 trial participants during the trial, including compliance with safety reporting
2789 requirements between sponsors and investigators, regulatory authorities and
2790 IRBs/IECs and informing trial participants of safety information as necessary;
- 2791 (p) Documents that service providers are suitably qualified for conducting their
2792 delegated or transferred activities;
- 2793 (q) Documents that laboratory activities and other tests used in the trial are fit for
2794 purpose;
- 2795 (r) Documents sponsor oversight of investigator site selection and monitoring and
2796 audit of the trial, where appropriate, and provides information on arising
2797 issues/non-compliance and deviations detected and implementation of
2798 corrective and preventative actions;
- 2799 (s) Documents the compliance with the protocol and/or procedures for
2800 management and statistical analysis of the data and production of any interim
2801 report and the final report;
- 2802 (t) Documents the collection, chain of custody, analysis and retention or
2803 destruction of biological samples;
- 2804 (u) Provides relevant information on the investigational product and its labelling;
- 2805 (v) Provides information about the shipment, storage, packaging, dispensing,
2806 randomisation and blinding of the investigational product;
- 2807 (w) Provides, where appropriate, traceability and accountability information about
2808 the investigational product from release from the manufacturer to dispensation,

- 2809 administration to trial participants, and return and destruction, or alternative
2810 disposition;
- 2811 (x) Provides information on the identity and quality of the investigational product
2812 used in the trial;
- 2813 (y) Documents processes and activities relating to unblinding;
- 2814 (z) Documents the recruitment, pre-trial screening and consenting process of trial
2815 participants and their identity and chronological enrolment as appropriate;
- 2816 (aa) Documents the existence of the trial participants and substantiates the integrity
2817 of trial data collected. Includes source records related to the trial and medical
2818 treatments and history of the trial participants;
- 2819 (bb) Defines processes/practices in place in the event of a security breach in order to
2820 protect participants' rights, safety and well-being and the integrity of the data.
- 2821 C.3.2 Applying the criteria in section C.3.1, the trial records for every trial that are
2822 considered essential, except in justifiable and documented exceptional circumstances,
2823 are set out in Table 1, and these should be retained.
2824
- 2825 C.3.3 For other trial records, their presence and nature are dependent upon the trial design,
2826 its conduct and risk proportional management. Table 2 lists potential trial records that
2827 when generated, would be considered essential by applying the criteria in section
2828 C.3.1 and should be retained. This is not an exhaustive list, and other trial records may
2829 also be considered essential by the sponsor or the investigator.
2830

	Table 1 – Essential Records for All Trials
1.1	Investigator's Brochure or basic product information brochure (e.g., summary of product characteristic, package leaflet or labelling) and relevant updates
1.2	signed protocol and amendments during the trial
1.3	dated, documented approval/favourable opinion of IRB/IEC of information provided to them before and during the trial
1.4	IRB/IEC composition
1.5	regulatory authority(ies) authorisation, approval and/or notification of the protocol and subsequent protocol amendments during the trial (where required)
1.6	completed signed and dated informed consent forms
1.7	completed participant identification code list and enrolment log
1.8	- notification by originating investigator to sponsor of serious adverse events (SAEs) and related reports, where required - notification by sponsor and/or investigator, where required, to regulatory authority(ies) and IRB(s)/IEC(s) of suspected unexpected serious adverse reactions (SUSARs) and of other safety information - notification by sponsor to investigators of safety information, where required
1.9	interim or annual reports to IRB/IEC and regulatory authority(ies)
1.10	source records

	Table 1 – Essential Records for All Trials
1.11	data and relevant metadata (including documentation of data corrections) in the data acquisition tools
1.12	final report by investigator to IRB/IEC and regulatory authority(ies), where required
1.13	interim (where applicable) and final clinical trial reports

2831

	Table 2 – Potential Essential Records
2.1	sample of data acquisition tools (e.g., case report forms (CRFs), diaries, clinical outcome assessments, patient-reported outcomes) that are provided to the investigator and/or IRB/IEC
2.2	sample of information given to trial participants and revisions during the trial - informed consent materials (including all applicable translations) - any other documented information, e.g., instructions for use of an investigational product or a device - advertisement for participant recruitment
2.3	financial aspects of the trial
2.4	insurance statement
2.5	signed agreement between involved parties, e.g., - investigator/institution and sponsor - investigator/institution and service providers - sponsor and service providers - sponsor and independent data monitoring committee (IDMC) members
2.6	curriculum vitae and/or other relevant documents evidencing qualifications of investigator(s) and sub-investigator(s) involved in conducting the trial
2.7	trial-specific training records
2.8	documentation of delegation of activities by the investigator to investigator site staff
2.9	signature sheet documenting signatures and initials of delegated investigator site staff
2.10	normal value(s)/range(s) for medical/laboratory/technical procedure(s) and/or test(s) included in the protocol and updates during the trial conduct
2.11	certification or accreditation or established quality control and/or external quality assessment or other validation (where required) of medical/laboratory/technical procedures/tests used during the trial conduct and any updates
2.12	documentation of collection, processing and shipment of body fluids/tissue samples
2.13	documentation of body fluids/tissue samples storage conditions
2.14	record of retained body fluids/tissue samples at the end of the trial
2.15	sample of label(s) attached to investigational product container(s)
2.16	instructions for handling of investigational product(s) and trial-related materials (if not included in protocol or Investigator's Brochure), for example, pharmacy manual
2.17	shipping records for investigational product(s) and trial-related materials
2.18	certificate(s) of analysis of investigational product(s) shipped

	Table 2 – Potential Essential Records
2.19	investigational product(s) accountability at investigator site
2.20	documentation of investigational product storage conditions during shipment and at the trial site
2.21	records of relabelling of investigational product at trial site
2.22	documentation of investigational product destruction
2.23	emergency decoding procedures for blinded trials
2.24	master randomisation list
2.25	instructions for use for critical trial-specific systems (e.g., interactive response technologies (IRT) user manual, electronic CRF (eCRF) manual)
2.26	maintenance and calibration records for critical trial-specific equipment
2.27	treatment allocation and decoding documentation
2.28	completed participants screening log
2.29	site monitoring reports (including site selection, initiation, routine and close-out)
2.30	centralised monitoring reports
2.31	records and reports of protocol and GCP non-compliance/deviations and corrective and preventative actions
2.32	documentation of relevant communications and meetings
2.33	audit certificate
2.34	documentation relating to data finalisation for analysis (e.g., query resolutions, SAE reconciliation, quality control reports, coding completion, output data sets)
2.35	documentation of trial-specific computerised system validation (e.g., specifications, testing, validation report, change control)
2.36	documentation relating to the statistical considerations and analysis (e.g., sample size calculations, analysis sets decisions, analysis datasets, analysis programs, quality control records and output)
2.37	trial-specific plans (e.g., risk management, monitoring, safety, data management, data validation and statistical analysis) and procedures
2.38	procedures, meeting minutes and submissions to the IDMC